Document:

Development and License Agreement between Schering AG and Registrant

  
 EXHIBIT 10.10

  
 DEVELOPMENT AND LICENSE AGREEMENT 
  
 THIS AGREEMENT is made the 2nd day of October 2003 by and between Exhale Therapeutics, Inc., a U.S. corporation having its principal place of business at 1301 Shoreway Road, Suite 320,
Belmont, California 94002, U.S.A. (hereinafter referred to as “Exhale”) and Schering Aktiengesellschaft, a corporation organized and existing under the laws of Germany having its principal place of business at Muellerstraße 178,
13353 Berlin, Germany (hereinafter referred to as “Schering”). Schering and Exhale are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 
  
 WITNESSETH: 
  
 WHEREAS, Schering is engaged in the development of the Substance (hereinafter defined) in the Field (hereinafter defined)
for the European Union and has been granted regulatory approval of the Substance in the Field by the European Commission; 
  
 WHEREAS, Exhale is interested in developing and commercializing the Substance in the Field for the U.S. and obtaining from Schering certain rights and
licenses therefor, and Schering is willing to grant such rights and licenses to Exhale under the terms and conditions hereinafter set forth. 
  
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants and agreements contained herein, the Parties hereto, intending to be
legally bound, do hereby agree as follows: 
  
 ARTICLE I

  
 DEFINITIONS 
  
 The following terms, when capitalized, shall have the following meanings
(such meanings to be equally applicable to both the singular and plural forms of the terms defined), when used in this Agreement. 
  
 “Affiliate” means, with respect to a Party, any person, corporation, firm, joint venture, or other entity which, directly or indirectly, by
itself or through one or more intermediaries, controls, is controlled by, or is under common control with such Party. As used in this definition, the term “control” means the possession of the power to direct or cause the direction of the
management and policies of an entity, whether through the ownership of the outstanding voting securities or by contract or otherwise. 
  
 “Agreement” means this Development and License Agreement. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 “ANDA” means a drug application filed with the FDA to obtain marketing approval for a generic
product. 
  
 “Audit Disagreement” shall have the meaning
set forth in Section 8.10(b). 
  
 “Best Efforts” means
the highest level of endeavor which a prudent business person in the prescription pharmaceutical industry would reasonably expend to accomplish an important objective. 
  
 “Business Day” means a day which is not a Saturday, a Sunday or other day on which banks are required or
authorized by law to be closed in New York, U.S., or in Berlin, Germany. 
  
 “CFR” means the US Code of Federal Regulations. 
  
 “Clinical Development” means the conduct of studies of the Product in humans in the Field to assess the dosing, safety and/or efficacy of the Product, including but not limited to Phase 1 Clinical Trials,
Phase 2 Clinical Trials and Phase 3 Clinical Trials. 
  
 “Commercialization” and “Commercialize” shall refer to all activities undertaken relating to the use, pre-marketing, marketing, sale, import for sale and distribution of the Product. 
  
 “Commercialization Plan” shall mean the document attached hereto as
Schedule 3. 
  
 “Commercially Reasonable Efforts” means
the level of endeavor which a prudent business person in the prescription pharmaceutical industry would ordinarily expend to accomplish an important objective. 
  

“Confidential Information” shall have the meaning set forth in Section 10.1. 
  
 “Control” or “Controlled” means the right to grant an exclusive license or sublicense of patent rights,
know-how, information or other intangible rights as provided for herein without violating the terms of any agreement or other arrangement with any Third Party. 
  

“Development” and “Develop” mean all activities relating to the Pre-clinical Development and Clinical Development of the Product in
the Field. 
  
 “Development and Commercialization
Committee” means the committee established by the parties pursuant to Section 5.1. 
  
 “Development Plan” shall mean the document attached hereto as Schedule 2. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 2 

 “DMF” shall mean the drug master file concerning Drug Substance and Drug Product in the Field.

  
 “Domain Names” means any domain name identical or
confusingly similar with the Trademarks owned or controlled by Schering and used by Exhale for the Commercialization of the Product in the Field in the Territory. 
  
 “Drug Approval Application” means an application for Regulatory Approval which is required before commercial sale
or use of the Product as a drug in the Territory. 
  
 “Drug
Product” shall mean the pharmaceutical product for inhaled use which includes, as an active ingredient, the Substance (hereinafter defined), and complies with the relevant Specifications (hereinafter defined). 
  
 “Drug Substance” shall mean Schering’s proprietary compound
Iloprost in acid form, and complies with the relevant Specifications (hereinafter defined).  
  
 “Effective Date” shall mean the date when the Agreement is executed by both Parties and Exhale has provided written proof to Schering that it
has entered into an agreement with investors for at least USD 15 million of additional funding available for the Development and Commercialization of the Product in the Field in the Territory (as defined hereinafter). 
  
 “FDA” means the U.S. Food and Drug Administration, or any successor
health regulatory authority. 
  
 “Field” means inhaled
use of the Substance and/or Product in the indication “pulmonary hypertension” in humans. 
  
 “First Commercial Sale” means the date Exhale or an Affiliate or sublicensee of Exhale first sells commercially, pursuant to Regulatory
Approval, the Product in the Territory. 
  
 “Health
Regulatory Authority” means the FDA. 
  
 “IND”
means an Investigational New Drug application filed with the FDA pursuant to 21 CFR 312.1 et seq. 
  
 “Joint Inventions” shall have the meaning set forth in Section 11.1. 
  
 “Joint Patents” shall have the meaning set forth in Section 11.1. 
  
 “Know-how” means: (i) techniques, data and information relating to
the Substance, the Drug Substance, the Drug Product or the Product within the Field, including, but not limited to, inventions, practices, methods, manufacturing 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 3 

 
processes, knowledge, know-how, skill, trade secrets, experience, test data (including pharmacological, toxicological, preclinical and clinical test data);
data, records and information derived from Preclinical Development or Clinical Development, regulatory submissions, adverse reactions, analytical and quality control data, marketing, pricing, distribution, cost, sales and manufacturing data or
descriptions, and (ii) compound, compositions of matter and assays within the Field relating to the Substance, the Drug Substance, the Drug Product or the Product. 
  
 “Losses” shall have the meaning set forth in Section 13.1. 
  
 “Manufacture” or “Manufacturing” means all operations
required to manufacture, test, release, handle, store and destroy Drug Product or Drug Substance, or any step thereof, as the case may be. 
  
 “NDA” means a new drug application filed with the FDA to obtain marketing approval for the Product in the Field in the Territory (as defined
hereinafter). 
  
 “Net Sales” means gross sales by
Exhale or its Affiliates or any sublicensee of Product hereunder as reflected in invoices to unaffiliated Third Parties, less reasonable and customary deductions applicable to the Products for: 
  
 (a) transportation charges and insurance charges paid by Exhale; 

 
 (b) sales and excise taxes or customs duties or any other governmental
charges imposed upon the sale of the Product and paid by Exhale; 
  
 (c) allowances or credits to customers on account of governmental requirements, price differences, rejection, rebates, outdating, returns or recalls of the Product. 
  
 In the event the Product is sold in the form of a combination product containing one or more active ingredients in addition
to the Substance, Net Sales for such combination product will be adjusted by multiplying actual Net Sales of such combination product by the fraction A / (A+B) where A is the invoice price of the Product in which the Substance is the only active
ingredient, if sold separately, and B is the invoice price of any other active ingredient or ingredients in the combination, if sold separately. If the other active ingredient or ingredients in the combination are not sold separately, Net Sales
shall be calculated by multiplying actual Net Sales of such combination product by the fraction A / C where A is the invoice price of the Product in which the Substance is the only active ingredient if sold separately, and C is the invoice price of
the combination product. If neither the Product in which the Substance is the only active ingredient nor the other active component or components of the combination product is sold separately, Net Sales shall be determined by allocating actual Net
Sales of the combination product between the Substance and the other matter based upon the total actual sourcing cost thereof. 
  
 “Orphan Drug Application” means an application for Orphan Drug Approval. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 4 

 “Orphan Drug Approval” means the granting of the orphan drug status for the Product in the
Field by the Health Regulatory Authority. 
  
 “Orphan Drug
Status” means the period during which the Product is approved as an orphan drug. 
  
 “Patent Expenses” means the fees, expenses and disbursements and outside counsel and agent fees incurred in connection with the preparation, filing, prosecution and maintenance of Patents including
Schering’s and Exhale’s costs of patent interference, opposition and nullity proceedings. 
  
 “Patents” means all patents, patent applications and patent applications hereinafter filed in any country of the world, including any
continuation, continuation-in-part, division, provisional or any substitute applications, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplemental patent
certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing. 
  
 “Phase 3 Clinical Trials” has the meaning set forth in 21 CFR 312.21(c), as amended. 
  
 “Pre-clinical Development” means all activities relating to the
planning and execution of non-human studies conducted in in vitro or in relevant in vivo animal models directed toward obtaining Regulatory Approval of the Product in the Field in the Territory. This includes pre-clinical testing,
pharmacokinetics, toxicology, documentary and medical writing directly related to Pre-clinical Development activities, and related regulatory affairs. 
  
 “Product” means any pharmaceutical product for inhaled use which includes, as an active ingredient the Substance (hereinafter defined).

  
 “Regulatory Approval” means the approval by the
Health Regulatory Authority necessary for the Commercialization of the Product in the Field in the Territory. 
  
 “Schering Know-how” means Know-how within the Control of Schering as of the Effective Date or which comes within the Control of Schering during
the term of this Agreement and relates to the Development, Manufacture or Commercialization of the Substance, the Drug Substance, the Drug Product or the Product in the Field in the Territory. Notwithstanding anything herein to the contrary,
Schering Know-how shall exclude Schering Patents. 
  
 “Schering Patents” means any Patents in the Territory owned or Controlled by Schering or its Affiliates as of the Effective Date or which comes within the ownership or Control of Schering or any of its Affiliates during the term
of this 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 5 

 
Agreement covering the Development, Manufacture, or Commercialization of the Substance, the Drug Substance, the Drug Product or the Product in the Field.

  
 “Specifications” shall mean the tests, standard test
methods and acceptance limits for qualitative and quantitative characteristics of Drug Product and Drug Substance as set out in Schedule 4 (attached hereto and made a part hereof), as same may be amended from time to time by mutual agreement of the
Parties. 
  
 “Substance” means Schering’s
proprietary compound Iloprost Trometamol. 
  
 “Supply
Interruption Event” shall be deemed to have occurred upon the completion of either (i) two (2) consecutive quarters, or (ii) any three (3) quarters in a period of seven (7) consecutive quarters, in each case during which Exhale has received
less than sixty percent (60%) of the amount of Drug Product or Drug Substance (as applicable) for which Exhale had placed a firm order. 
  
 “Territory” means the U.S. 
  
 “Third Party” means any entity other than Schering or Exhale and their respective Affiliates. 
  
 “Trademark” means any trademark owned and Controlled by Schering
and used by Exhale in connection with the marketing of the Product in the Field in the Territory. 
  
 “U.S.” shall mean the United States of America and its territories and commonwealths and possessions, including without limitation the
Commonwealth of Puerto Rico. 
  
 “Valid Claim” shall
mean a claim in an issued, unexpired Schering Patent which has not been abandoned, withdrawn, canceled or disclaimed, nor held invalid or unenforceable by a court of competent jurisdiction in an unappealed or unappealable decision. 
  
 ARTICLE II 
  
 LICENSES TO PATENTS AND KNOW-HOW 
  

	2.1	As of the Effective Date of this Agreement, Schering hereby grants to Exhale the exclusive (even as to Schering) right and license under the Schering Patents and the Schering
Know-how to Develop and Commercialize the Product in the Territory and within the Field, subject to the terms and conditions hereof. 

  
 The granting of sublicenses by Exhale under the licenses set forth in this Agreement to Affiliates of Exhale or any Third Party shall be subject to

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 6 

 
Schering’s prior written consent; such consent not to be unreasonably withheld. 
  

	2.2	A list of the Schering Patents identified as of the Effective Date is attached hereto as Schedule 1. If at any time during the course of this Agreement any additional Patents are
acquired by or come under the Control of Schering that include any claims that are necessary or desirable for the Development, Manufacture or Commercialization of the Product in the Territory in the Field, such shall be added to the list attached
hereto as Schedule 1. 

  

	2.3	Promptly following the Effective Date, Schering shall disclose and provide to Exhale all Schering Know-how which is available at Schering and required for the Development or
Commercialization of the Product in the Field in the Territory (except for the DMF). If at any time during the course of this Agreement any additional Know-how necessary or desirable for the Development or Commercialization of the Product in the
Territory in the Field is acquired by, Controlled by, or otherwise becomes available to Schering, Schering shall promptly offer to Exhale to provide all such additional Know-how. If Exhale accepts this offer to receive such additional Know-how and
such additional Know-how is acquired from a Third Party against payment of a license or a lump sum fee, such fee shall be borne by Exhale, but fifty (50) percent of such may be deducted from the royalty otherwise payable to Schering pursuant to
Article VIII of this Agreement. 

  

	2.4	Notwithstanding the rights granted to Exhale pursuant to Section 2.1 above, Schering at all times reserves the right under the Schering Patents and the Schering Know-how to Develop,
Manufacture or Commercialize the Substance and/or the Product in any country of the world for any use outside the Field, and outside the Territory for any use either within or outside the Field. 

  

	2.5	Exhale covenants that it shall not use any of the Schering Know-how or Schering Patents to carry out any activity or exercise any right other than those expressly licensed by
Schering to Exhale pursuant to this Agreement. 

  
 ARTICLE III 
  
 DEVELOPMENT 
  

	3.1	Development 

  

	 	(a)	From the Effective Date, Exhale shall solely be responsible for and bear all costs of all Development of the Product in the Field in the Territory. 

  

	 	(b)	The expected Development to be conducted by Exhale pursuant to Section 3.1 (a) above including, but not limited to the timelines for such 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 7 

	 	 
Development shall be set out in the Development Plan attached hereto as Schedule 2. Any material change of or material deviation from this Development Plan
and any material redefinition of development goals and strategy requires Schering’s prior written consent, which shall not be unreasonably withheld and shall be deemed given if a refusal with a written explanation is not provided to Exhale
within fifteen (15) Business Days of Exhale’s request for such consent. 

  

	 	(c)	Exhale shall use Best Efforts to Develop the Product in accordance with the timelines set out in the Development Plan and to obtain Regulatory Approval for the Product in the Field
and bring the Product to market in the Territory by the dates specified in the Development Plan. 

  

	 	(d)	Exhale will refrain from any and all activities (other than those contemplated under this Agreement) which are likely to have a negative impact on the Development or
Commercialization of the Product outside the Territory. 

  

	3.2	Clinical Development Applications, Drug Approval Application and Orphan Drug Application 

  

	 	(a)	Exhale shall be responsible for the preparation, filing and prosecution of applications for permission to conduct Clinical Development in the Field in the Territory.

  

	 	(b)	Exhale shall be responsible for the preparation, filing and prosecution of the Drug Approval Application and Orphan Drug Application and shall seek Regulatory Approval and Orphan
Drug Approval for the Product in the Field in the Territory, including preparing all reports necessary as part of the Drug Approval Application or the Orphan Drug Approval. The Drug Approval Application and the Orphan Drug Application shall be filed
in the name of Exhale, and a copy of such Drug Approval Application and Orphan Drug Application shall be promptly provided to Schering. The DMF shall, however, be kept with and filed with the Health Regulatory Authority by Schering; Exhale shall be
authorized to refer to the DMF in its Drug Approval Application. In connection with the Drug Approval Application and the Orphan Drug Application being prosecuted by Exhale under this Section 3.2, Exhale agrees to provide Schering with a copy (which
may be wholly or partly in electronic form) of all filings to the Health Regulatory Authority that it makes hereunder, such copy to be provided at the same time as Exhale makes the filing with the Health Regulatory Authority.

  

	 	(c)	Cooperation. Exhale shall inform and consult with Schering prior to each regulatory submission to the Health Regulatory Authority, provided however, that prior to and following
Regulatory Approval or Orphan Drug Approval, Exhale shall be solely responsible for 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 8 

	 	 
interactions with Health Regulatory Authority. As between the Parties, Exhale shall be the legal and beneficial owner of the Drug Approval Application and
the Orphan Drug Application and related Regulatory Approval and Orphan Drug Approval in the Territory. 

  

	3.3	Support by Schering 

  
 At Exhale’s request, Schering shall provide Exhale with reasonable support in the form of consulting services directed toward securing and
maintaining Regulatory Approval and Orphan Drug Approval. In the first twelve (12) months after the Effective Date, Schering shall provide fifty (50) person hours per month of such consulting services free of charge as and when reasonably requested
by Exhale. Any consulting services by Schering after the first twelve (12) months or beyond fifty (50) hours per month during the first twelve (12) months shall be reimbursed by Exhale for time and expenses at pre-approved fully burdened cost
according to general accounting principles. Travel time associated with rendering such services shall be included as consulting time (not more than eight (8) hours per day). The parties agree that membership in the Development and Commercialization
Committee is not deemed to be the provision of consulting services and Exhale shall not reimburse any costs related to Schering’s participation in the Development and Commercialization Committee. 
  
 In addition, from the Effective Date, Exhale shall reimburse to Schering
reasonable, pre-approved traveling and accommodation expenses incurred in providing the aforementioned consulting services. 
  
 ARTICLE IV 
  
 COMMERCIALIZATION 
  

	4.1	Exhale as Sole Commercialization Party. Exhale shall have the exclusive right to Commercialize the Product, either by itself or through its Affiliates in the Field in the Territory.

  

	4.2	Commercialization Plan. The expected Commercialization to be conducted by Exhale pursuant to this Section 4 shall be set out in the Commercialization Plan attached hereto as
Schedule 3. Any material change of or material deviation from this Commercialization Plan and any material redefinition of commercialization goals and strategy requires Schering’s prior written consent, which shall not be unreasonably withheld
and shall be deemed given if a refusal with a written explanation is not provided to Exhale within fifteen (15) Business Days of Exhale’s request for such consent. 

  

	4.3	Commercialization Efforts. Exhale agrees to use Best Efforts with respect to the Commercialization of Products in the Field in the Territory as provided hereunder. Without limiting
the generality of the foregoing, Exhale shall 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 9 

	 	 
determine the pricing for the Product at its sole discretion, provided, however, that Exhale shall not sell the Product as a loss leader.

  

	4.4	Marketing and Sales Infrastructure. Exhale agrees to Commercialize the Product on the basis of a marketing and sales infrastructure which is specifically qualified for and
specifically concentrates on the Commercialization of the Product. The Commercialization through a Third Party shall only be permissible upon Schering’s prior written consent, except for the use of specialty pharmacies in the normal course of
distribution. 

  

	4.5	Exhale will not seek customers or establish any branch or commercialization depot for the Product in any country which is outside the Territory. Exhale will not, neither knowingly
nor if it gross negligently does not know, supply the Product to any customer outside the Territory or to any customer in the Territory for resale outside the Territory unless such supply is required by law. 

  
 Neither Schering nor any of its Affiliates will seek customers or establish
any branch or commercialization depot for the Product in the Field in the Territory. Schering and its Affiliates will not, neither knowingly nor if they gross negligently do not know, supply Product to any customer in the Territory or outside the
Territory for resale in the Field in the Territory unless such supply is required by law. 
  
 ARTICLE V 
  
 COOPERATION BETWEEN
THE PARTIES 
  

	5.1	Development and Commercialization Committee. Within thirty (30) days of the Effective Date, Schering and Exhale will establish a Development and Commercialization Committee. The
Development and Commercialization Committee will be composed of six (6) members, three (3) representatives appointed by Schering and three (3) representatives appointed by Exhale. Such representatives will include individuals with expertise in areas
such as clinical development, regulatory affairs and marketing. The Development and Commercialization Committee will meet (in person, telephonically or via videoconference). Upon reasonable request of either Party, employees of the Parties who have
expertise in certain other areas may attend meetings of the Development and Commercialization Committee as guests. Unless otherwise agreed between the Parties, meetings of the Development and Commercialization Committee shall take place quarterly.
One of the Exhale members of the Development and Commercialization Committee, chosen at the sole discretion of Exhale, along with one of the Schering members of the Development and Commercialization Committee, chosen at the sole discretion of
Schering, shall serve as co-chairs of the Development and Commercialization Committee. Either Party may replace any or all of its representatives at any time upon written notice to the other Party. If any issues or disputes cannot be resolved
unanimously within the Development 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 10 

	 	 
and Commercialization Committee, these issues shall be referred to Exhale’s CEO and the President of the Strategic Business Unit (“SBU”)
Specialized Therapeutics at Schering’s Affiliate Berlipharm, Inc., Montville, New Jersey, U.S.A., for resolution. If Exhale’s CEO and the President of the SBU Specialized Therapeutics cannot resolve the issue unanimously, Exhale’s CEO
shall discuss this issue with the board member of Schering who is responsible for the SBU Specialized Therapeutics. Should Exhale’s CEO and Schering’s board member not come to an unanimous resolution (i) with respect to an issue that could
be reasonably expected to have an adverse effect on Schering’s Product business outside the Territory, then Schering shall have the final decision, and (ii) with respect to any other issue, Exhale shall have the final decision, provided that
Exhale agrees to solely bear its increased cost or expense resulting from such decision. Each Party will disclose to the other proposed agenda items reasonably in advance of each meeting of the Development and Commercialization Committee. Each Party
shall bear its own costs for participation in the Development and Commercialization Committee. 

  

	5.2	Functions of Development and Commercialization Committee: The Development and Commercialization Committee shall: (a) discuss and supervise the development of the Product in the
Field in the Territory, including the progress and conduct of the Development, meeting Development goals, dealing with obstacles to successful Development, and the status of obtaining the Regulatory Approval; (b) discuss and supervise the
Commercialization of the Product, including the progress and conduct of the Commercialization, meeting Commercialization goals and dealing with obstacles to successful Commercialization; (c) discuss and supervise actions planned by Exhale in respect
of the Product where such actions could reasonably be expected to have a material impact on the Product in the Territory or outside the Territory; and (d) discuss in good faith other issues relating to the Commercialization of the Product in the
Territory and outside the Territory. All discussions and other activities of the Development and Commercialization Committee shall be subject to Article X of this Agreement. 

  

	5.3	Reports. Exhale shall provide to Schering no later than two (2) weeks before each meeting of the Development and Commercialization Committee a report detailing and evaluating all
issues relating to Sections 5.2 (a) to (d) above. Schering shall inform Exhale no later than one (1) week before each meeting of the Development and Commercialization Committee of any specific issues which it intends to discuss.

  

	5.4	Use of Data. Subject to Article X of this Agreement, Schering shall be authorized to use any and all Know-how generated or acquired by Exhale relating to the Product in the Field
under this Agreement in accordance with the license granted in Section 11.3(c) hereof. Exhale shall promptly upon such generation of Know-how offer to Schering to provide such newly generated or acquired Know-how to Schering. If Schering accepts to
receive such Know-how and such Know-how is acquired from a Third Party against payment of a license or a lump sum fee, half of such fee shall be borne by Schering. 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 11 

 ARTICLE VI 
  
 MANUFACTURE OF CLINICAL AND COMMERCIAL SUPPLY 
  

	6.1	Schering shall Manufacture or have Manufactured by an Affiliate or a Third Party and supply to Exhale Drug Product as and when reasonably requested and in accordance with the
relevant Specifications, and, subject to the terms of this Article VI (and prior to the Notice Period), Exhale shall purchase exclusively from Schering all Drug Product which is required for conduct of Clinical Development and Commercialization of
the Product in the Field in the Territory. With respect to this Manufacture and supply of the Drug Product by Schering, Schering shall provide Exhale priority that is at least as high as the priority Schering applies to its own internal requirements
for Drug Product and Drug Substance or any other higher priority Iloprost substance or product. The parties will determine and specify reasonably and in good faith a more detailed process for such Manufacture and supply consistent with the terms of
this Article VI in the form of a manufacturing and supply agreement to be completed within two (2) months from the execution of this Agreement (hereinafter the “Manufacturing & Supply Agreement”).  

  

	6.2	The ex works price for paper, one-color labeled ampoules, packed in a 300-ampoule boxes for Commercialization of Drug Product per ampoule shall be as follows:

  

			
	 - for a firm order of [***] to [***] million ampoules per year:
	  	EUR [***];
		
	 - for a firm order of more than [***] to [***] million ampoules per year:
	  	EUR [***];
		
	 - for a firm order of more than [***] million ampoules per year:
	  	EUR [***].

  
 The ex works price
for Drug Substance (if applicable) shall be EUR [***] per gram. 
  
 These amounts shall be adjusted from January 1 of each calendar year in order to keep pace with inflation or deflation. The adjustment shall be in accordance with the change of the “Price Index for Cost of Living of all Private
Households” by the German Federal Statistical Office for the respective previous year. 
  

	6.3	At any time during the term of this Agreement or the Manufacturing & Supply Agreement, Schering may terminate the Manufacture and supply of Drug Product to Exhale if Schering
decides to generally cease Manufacture of Drug Product (and/or Drug Substance if Schering decides to generally cease manufacture thereof) with twenty four (24) months’ (the “Notice Period”) prior written notice to Exhale provided
that: 

  

	 	(a)	With effect as of the expiry of the Notice Period, Exhale is automatically 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 12 

	 	 
granted the non-exclusive right and license under the Schering Patents and the Schering Know-how to Manufacture Drug Substance and/or Drug Product (as
applicable) or have Drug Substance and/or Drug Product (as applicable) Manufactured through a contract manufacturer for Clinical Development and Commercialization of the Product in the Field in the Territory (hereafter the “Manufacturing
License”). From the beginning of the Notice Period, Exhale is automatically granted the non-exclusive right and license to prepare such Manufacture of Drug Substance or Drug Product (as applicable). 

  
 If, after the beginning of the Notice Period, Schering wishes to grant a
(non-exclusive) Manufacturing License to a Third Party, Schering shall, before entering into any agreement with any Third Party offer to Exhale in writing to take an exclusive Manufacturing License. Exhale shall within thirty (30) days of receipt of
the written offer evaluate its interest in the exclusive Manufacturing License. If, after thirty (30) days, Exhale decides not to take the exclusive Manufacturing License, Schering shall be free to grant a non-exclusive Manufacturing License to any
Third Party. If, however, after thirty (30) days, Exhale wishes to take the exclusive Manufacturing License, Schering and Exhale will negotiate reasonably and in good faith binding commercially reasonable terms of an exclusive Manufacturing License
within additional forty-five (45) days. Should Schering and Exhale not come to an agreement concerning the exclusive Manufacturing License during this additional forty-five (45) days’ period, Schering shall be free to grant a non-exclusive
Manufacturing License to any Third Party. 
  

	 	(b)	Promptly following its written notice to Exhale pursuant to this Section 6.3, Schering shall disclose and provide to Exhale all Schering Know-how which is available at Schering and
required for the Manufacture of the Drug Product and/or Drug Substance (as applicable) in the Field in the Territory. Section 2.3 sentences 2 and 3 shall apply mutatis mutandis. 

  

	 	(c)	At Exhale’s request, Schering shall provide Exhale or its designated contract manufacturer with reasonable support in the form of consulting services directed towards the
completion of the transfer of the Manufacture to Exhale or its designated contract manufacturer. This support shall be provided within the framework determined in Section 3.3 above and shall include an additional two hundred and fifty (250) person
hours free of charge. 

  

	 	(d)	No later than by one (1) month before the expiry of the Notice Period, Schering shall supply to Exhale Drug Substance against payment of EUR [***] per gram in the amount which is
required to Manufacture Drug Product required for Commercialization of Product during a period of two (2) years based on Exhale’s forecast. This forecast by Exhale must be submitted to Schering no later than six (6) months before the expiry

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 13 

	 	 
of the Notice Period. In addition, throughout the Notice Period, Schering shall supply to Exhale on the same terms Drug Substance in the amount required by
Exhale to establish Manufacturing operations by the expiry of the Notice Period. The price per gram shall be adjusted pursuant to Section 6.2 sentence 2 above. If Schering has elected to terminate supply of Drug Product in accordance with this
Section, but not Drug Substance, Schering’s supply and license obligations under this Agreement (and under the Manufacturing and Supply Agreement) shall apply mutatis mutandis to Drug Substance in lieu of Drug Product as of the expiry of
the Notice Period. 

  

	6.4	Schering may permanently cease Manufacture and supply of Drug Substance and/or Drug Product without giving twenty four (24) months’ prior written notice if any regulatory
authority in any major market country outside the Territory requires the Drug Substance and/or Drug Product to be withdrawn from the market for safety reasons and Schering implements such withdrawal on a worldwide basis. In such event, Schering will
give Exhale such notice as is reasonable in the circumstances. Following notice by Schering under this Section 6.4, the provisions of Sections 6.3 (a), (b) and (c) above shall apply mutatis mutandis except that the Manufacturing License is
granted immediately upon receipt of Schering’s respective notice by Exhale. 

  

	6.5	The provisions of Sections 6.3 above shall also apply mutatis mutandis in the event of a Supply Interruption Event except that the Manufacturing License is granted
immediately upon the occurrence of the Supply Interruption Event. This shall, however, not apply if Exhale terminates the Agreement in the event of a Supply Interruption Event pursuant to Section 14.2 (b) hereof. 

  

	6.6	The Parties agree that Schering shall not be liable to Exhale for any indirect, incidental, special or consequential damages (including without limitation any damages arising from
lost profits) arising out of or in connection with any short fall or disruption of supply of Drug Product or Drug Substance for which Exhale had placed a firm order including, but not limited to a Supply Interruption Event. 

 

	6.7	In the event that the provisions of Section 6.3 or 6.5 are triggered, if Exhale incurs Manufacturing or acquisition costs for Drug Product or Drug Substance that exceed the cost
that had been paid to Schering therefor by [***] percent ([***]%), any cost exceeding such [***] percent ([***]%) cost increase shall be shared equally between Schering and Exhale to the effect that Exhale may deduct the respective amount from the
royalty otherwise payable to Schering pursuant to Article VIII hereof; such deduction shall, however, only be permissible up to an amount of [***] percent ([***]%) of these royalties otherwise payable to Schering. 

  

	6.8	Schering shall be free to change the Manufacturing process for Drug Product or Drug Substance provided that the Specifications of Drug Product or Drug Substance shall be equivalent
to or better than the Specifications in existence 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 14 

	 	 
prior to such change. Schering shall inform Exhale in advance in writing of any such change of the Manufacturing process. 

  

	6.9	Exhale undertakes to include in its firm orders for Drug Product or Drug Substance (as applicable) under the Manufacturing and Supply Agreement capacity in order to ensure the
maintenance by Exhale of a continuous safety stock of Drug Product or Drug Substance (as applicable) covering at least Exhale’s requirements of Drug Product or Drug Substance (as applicable) for a period of two (2) months as calculated pursuant
to the then current forecast for the next two (2) months following the respective firm order. 

  
 ARTICLE VII 
  
 INITIAL PAYMENT AND MILESTONE PAYMENTS 
  

	7.1	Initial Payment. Exhale shall pay to Schering a non-refundable signing fee equal to six (6) million US dollars (US$ 6,000,000) within five (5) Business Days of the Effective Date of
this Agreement, provided that the payment of the US$ 750,000.— which Exhale paid to Schering following the Memorandum of Understanding between the Parties dated June 20, 2003 shall be credited towards the signing fee. 

 

	7.2	Milestone Payments. Exhale shall make the following one-time payments (“Milestone Payments”) to Schering within thirty (30) Business Days after the first achievement of
each of the following milestones. 

  

			
	 MILESTONES

	  	PAYMENT (US$)

	 Upon first acceptance for filing of the Product NDA in the Field by the Health Regulatory Authority
	  	7,000,000
	 Upon Regulatory Approval of the Product in the Field by the Health Regulatory Authority
	  	9,000,000
	 When annual Net Sales of the Product first exceed US$ 25 million
	  	4,000,000
	 When annual Net Sales of the Product first exceed US$ 100 million
	  	10,000,000

  
 Exhale shall notify
Schering promptly in writing of the occurrence of any of the above milestones. 
  
 ARTICLE VIII 
  
 ROYALTIES

  

	8.1	Royalty Rate. In further consideration of the rights and licenses granted to Exhale under Article II of this Agreement, Exhale shall pay to Schering royalties based on Net Sales of
the Product in the amount of [***]%. The sums to be paid by Exhale shall be exclusive of the costs for the supply of the Drug Product or Drug Substance pursuant to Article VI above. 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 15 

	8.2	Royalty Term: Except where expressly provided otherwise in this Agreement, all royalties shall be calculated from the date of the First Commercial Sale of the Product until the
later (the “Royalty Expiration Date”) of (i) ten (10) years from the First Commercial Sale of Product and (ii) the last to expire of any Patent which includes a Valid Claim applicable to the Product in the Territory.

  

	8.3	Royalty Reduction. Should (1) the Patents and the Orphan Drug Status expire before the Royalty Expiration Date and there be no Patent containing at least one Valid Claim and no
Orphan Drug Status and no other statutory exclusivity be in place which would prevent the sale of a generic version of the Product, and should, in this situation, any generic product occur or (2) the Product be approved by the Health Regulatory
Authority outside the Field based on an application by Schering, any of Schering’s Affiliates or a licensee of Schering other than Exhale (hereinafter the “Second Product”), and should this Second Product be used off-label in the
Field, and should sales of these generic products or sales of the Second Product for off-label use in the Field exceed [***] percent ([***] %) of Exhale’s Net Sales in any six (6) months period (as measured for generic products by IMS data
or similar data, and for off-label use through a recognized independent Third Party audit, such as IMS NDTI), then the royalty rate set out in Section 8.1 above shall over the period of three (3) years be reduced to [***] % as follows: (i) by
[***] percentage points to [***] % from the beginning of the calendar quarter following the calendar quarter in which the generic competition or the sales of the Second Product for off-label use in the Field exceeded the threshold of [***]
percent [***]% of Exhale’s Net Sales for a period of six (6) months (hereinafter the “Royalty Reduction Date”); (ii) again by [***] percentage points to [***] % from the end of the calendar year following the Royalty Reduction
Date; (iii) again by [***] percentage points to [***] % from the end of the second calendar year following the Royalty Reduction Date; and, (iv) from the end of the third calendar year following the Royalty Reduction Date and at any time
thereafter, the royalty rate shall again be reduced by [***] percentage points and thus be [***] %. The royalty rate shall in no event be reduced to less than [***] % under the terms of this Section 8.3. For the avoidance of doubt, it is
set forth herein that the royalty reduction set forth in this Section 8.3 will be triggered only once. 

  

	8.4	License following Expiration. After the Royalty Expiration Date for the Product, Exhale shall thereafter have an exclusive (even as to Schering), paid-up license to Schering
Know-how to Develop, and Commercialize the Product in the Field in the Territory as set out in Article II hereof. Furthermore, if Exhale has taken over Manufacture of Product in the Field in the Territory pursuant to Sections 6.3, 6.4 or 6.5 hereof,
Exhale shall thereafter have a non-exclusive, paid up license to Schering Know-How to Manufacture the Product. 

  

	8.5	Payment Reports and Payments. Exhale shall make payments to Schering quarterly within thirty (30) days after the end of each calendar quarter in which Net Sales occurred, such
period to be extended to fourty five (45) days if sales are made and recorded by a sublicensee of Exhale. A report summarizing the Net Sales of the Product during the relevant quarter shall be delivered to Schering within thirty (30) days or fourty
five (45) days (as 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 16 

	 	 
applicable) following the end of each calendar quarter for which payments are due. 

  

	8.6	Payments; Interest. Payments due under this Agreement shall be due on such date as specified in this Agreement and, in the event such date is not a Business Day, then the next
succeeding Business Day, and shall be made by wire transfer of immediately available funds to a bank account designated by Schering at least ten (10) days before payment is due. Any failure by Exhale to make a payment within five (5) Business Days
after the date when due, shall obligate Exhale to pay to Schering computed interest, the interest period commencing on the due date and ending on the payment day, at a rate per annum equal to the Prime Rate as publicly announced by Bank of America
on REUTERS_screen <USPRIME1> plus three (3) percentage points, or the highest rate allowed by law, whichever is lower. The interest calculation shall be based on the act/360 computation method. The interest rate shall be adjusted whenever
there is a change in the Prime Rate quotation on REUTERS screen <USPRIME1> mentioned above. Interest shall be compounded annually in arrears. Such interest shall be due and payable on the tender of the underlying principal payment.

  

	8.7	Taxes. Schering shall pay any and all taxes levied on account of all payments it receives under this Agreement. If laws or regulations require that taxes be withheld, Exhale will
(i) deduct those taxes from all remittable payments, (ii) timely pay the taxes to the proper taxing authority, and (iii) send proof of payment to Schering within thirty (30) days of receipt of confirmation of payment from the relevant taxing
authority. Exhale agrees to make lawful and reasonable efforts to minimize such taxes to Schering. 

  

	8.8	Payment Currency. Except for payments for Drug Product or Drug Substance pursuant to Article VI above, payments by Exhale under this Agreement shall be paid to Schering in U.S.
dollars. 

  

	8.9	Payments to or Reports by Affiliates. Any payment required under any provision of this Agreement to be made to either Party or any report required to be made by either Party shall
be made to or by an Affiliate of that Party if designated by that Party as the appropriate recipient or reporting entity without relieving such Party from responsibility for such payment or report. 

  

	8.10	Records of Revenues and Expenses. 

  

	 	(a)	Exhale will maintain complete and accurate records relevant to the calculation of revenues under this Agreement. Not more often than once each year, Exhale shall make the said
records available for inspection for the period required by applicable laws, but not less than two (2) years from creation of individual records by a certified public accountant or chartered accountant selected by Schering (subject to the consent of
Exhale not to be unreasonably withheld or delayed), for the sole purpose of verifying for Schering the correctness of 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 17 

	 	 
calculations and classifications of such revenues under this Agreement. Schering shall bear its own costs related to such audit; provided that, for any
underpayments greater than five (5) percent by Exhale, Exhale shall pay Schering the amount of underpayment, interest as provided for in Section 8.6 from the time the amount was due and Schering’s reasonable out-of-pocket expenses for such
audit. For any underpayments of less than five (5) percent by Exhale, Exhale shall pay Schering the amount of underpayment. Any overpayments by Exhale will be refunded to Exhale or credited to future royalties, at Exhale’s discretion. Any
records or accounting information received from Exhale shall be Confidential Information for the purposes of Article X. Results of any such audit shall be provided to both Parties and shall also constitute Confidential Information for the purposes
of Article X, provided that accountants are bound by appropriate confidentiality obligations and may only provide Schering with evidence of any royalty payment discrepancies. 

  

	 	(b)	If there is a dispute between the Parties following any audit performed pursuant to Section 8.10 (a), either Party may refer the issue (an “Audit Disagreement”) to an
internationally recognized independent certified public accountant or chartered accountant for resolution. In the event an Audit Disagreement is submitted for resolution by either Party, the Parties shall comply with the following procedures: (i)
the Party submitting the Audit Disagreement for resolution shall provide written notice to the other Party that it is invoking the procedures of this Section 8.10(b); (ii) within thirty (30) Business Days of the giving of such notice, the Parties
shall jointly select a recognized international accounting firm to act as an independent expert to resolve such Audit Disagreement. (iii) The Audit Disagreement submitted for resolution shall be described by the Parties to the independent expert,
which description may be in written or oral form, within ten (10) Business Days of the selection of such independent expert. (iv) The independent expert shall render a decision on the matter as soon as practicable. (v) The decision of the
independent expert shall be final and binding unless such Audit Disagreement involves alleged fraud, breach of this Agreement or construction or interpretation of any of the terms and conditions thereof. (vi) All fees and expenses of the independent
expert, including any third party support staff or other costs incurred with respect to carrying out the procedures specified at the direction of the independent expert in connection with such Audit Disagreement, shall be borne by each Party in
inverse proportion to the disputed amounts awarded to the Party by the independent expert through such decision (e.g. Schering disputes US$100, the independent expert awards Schering US$60, then Schering pays forty (40%) percent and Exhale pays
sixty percent (60%) of the independent expert’s costs). 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 18 

 ARTICLE IX 
  
 ADVERSE DRUG REACTIONS 
  

	9.1	Both parties agree to promptly exchange all information that relates to the safety of the Product and especially all adverse reactions and to comply with all applicable laws and
regulations relating to the Product concerning drug safety. 

  

	9.2	Within a period of two (2) months from the execution of the Agreement, and before enrolment of the first patient in a Product-related study that is conducted sponsored or
cosponsored by Exhale and before the first IND or NDA for the Product is granted to Exhale, the Parties will adopt a standard operating procedure to govern the investigation of and action to be taken with regard to Product-related adverse drug
experience reports (from both clinical studies and marketing experience), such that each of the Parties can comply with its legal obligations worldwide. The standard operating procedure will: (i) define responsibilities for adverse experience
handling for initial, follow-up and/or periodic submission to government agencies of significant information on the Product from pre-clinical laboratory, animal toxicology and pharmacology studies and pre-clinical and Clinical Development; and (ii)
include arrangements for the exchange of serious and non-serious cases including formats and timelines, periodic safety update reports, periodic reports and answers to safety-related queries by health regulatory authorities; and (iii) be promptly
amended as changes in legal obligations require or as otherwise agreed to by the Parties. 

  
 ARTICLE X 
  
 CONFIDENTIALITY 
  

	10.1	Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that the receiving Party shall keep
confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any Know-how and other information and materials furnished to it by the other Party pursuant to this Agreement or any
Know-how developed during the course of the collaboration hereunder, or any provisions of this Agreement that are the subject of an effective order of the Securities Exchange Commission granting confidential treatment pursuant to the Securities Act
of 1934 as amended (collectively “Confidential Information”), except to the extent that it can be established by the receiving Party that such Confidential Information: 

  

	 	(a)	was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party; or 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 19 

	 	(b)	was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; or 

  

	 	(c)	became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of
this Agreement. 

  

	 	(d)	was disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the disclosing Party not to disclose such
information to others; or 

  

	 	(e)	was independently discovered or developed by the receiving Party as documented in its corporate records. 

  

	10.2	Authorized Disclosure. Each Party may disclose Confidential Information hereunder to the extent such disclosure is reasonably necessary in filing or prosecuting patent applications,
prosecuting or defending litigation, filing or updating the drug approval applications or orphan drug applications, complying with applicable governmental laws, rules and regulations or conducting Development or Commercialization, provided that, if
a Party is required by law or regulation to make any such disclosures of the other Party’s Confidential Information it will, except where impracticable for necessary disclosures, for example in the event of medical emergency, give reasonable
advance notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the case of patent applications, will use its reasonable efforts to secure confidential treatment of such Confidential Information required
to be disclosed. In addition, and with prior written notice to the other Party of each Third Party with whom a confidential disclosure agreement is being entered into, each Party shall be entitled to disclose, under a binder of confidentiality,
Confidential Information to any Third Party for the purpose of carrying out the purposes of this Agreement. Nothing in this Article X shall restrict any Party from using for any purpose any Confidential Information independently developed by it
during the course of the collaboration hereunder, or from using Confidential Information that is specifically derived from pre-clinical or clinical trials to obtain regulatory approval or carry out marketing, sales or professional services support
functions as is customary in the pharmaceutical industry. Where materiality of disclosure requires a press release or other disclosure pertaining to this Agreement by one Party, the disclosing Party shall give at least three (3) Business Days’
advance notice to the other Party. 

  

	10.3	Termination of Prior Agreement and Negotiation Phase. The Parties agree that, as of the Effective Date, the Secrecy Agreement between the Parties dated June 25, 2002 is hereby
terminated and superseded by the provisions of this Agreement, and any disclosures made by Schering under the terms of the Secrecy Agreement shall be deemed to have been made under, and be governed solely by the terms of this Agreement. Furthermore,
the Parties agree that any disclosures made by either Party during the negotiations for 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 20 

	 	 
this Agreement shall be deemed to have been made under, and be governed solely by the terms of this Agreement. 

  

	10.4	Publications. Any press release or other major publication by Exhale relating to the Development or the Commercialization of the Product in the Field in the Territory shall be
provided to Schering at least ten (10) Business Days (or five (5) Business Days in the case of a press release) in advance of publication. Schering shall have the right to review and comment upon the publication and the parties will cooperate in
good faith to address any reasonable comments within such period. 

  

	10.5	Survival. This Article X shall survive the termination or expiration of this Agreement. 

  
 ARTICLE XI 
  
 OWNERSHIP OF INTELLECTUAL PROPERTY, PATENT RIGHTS, TRADEMARKS, DOMAIN NAMES AND USE OF NAME 
  

	11.1	Ownership. Each Party shall solely own, and it alone shall have the right to apply for, Patents within and outside of the Territory for any inventions made solely by that
Party’s employees or consultants in the course of performing work under this Agreement. Inventions made jointly by employees or consultants of Schering and Exhale relating to the use of the Product in the Field (herein referred to as
“Joint Inventions”) and any patents resulting therefrom (herein referred to as “Joint Patents”) shall be owned by the Parties jointly. Joint Inventions and Joint Patents may be used by either Party without accounting to or
further approval of the other Party, subject to Section 11.3(c). The granting of a license to any Third Party shall be subject to the other Party’s consent, such consent not to be unreasonably withheld. Either Party shall, however, be
authorized to license such Joint Invention or Joint Patent to any of its Affiliates without the other Party’s consent, subject to Section 11.3(c). 

  

	11.2	Disclosure of Inventions. Exhale shall disclose to Schering any invention made solely by its own employees or consultants relating to the Substance, Drug Substance, Drug Product or
the Product in the Field, and Schering shall disclose to Exhale any invention made solely by its own employees or consultants relating to the Substance, the Drug Substance (as applicable), the Drug Product or the Product in the Field in the
Territory reasonably in advance of the intended date for submission of a patent application to a governmental patent authority. 

  

	11.3	Patent Filings. 

  

	 	(a)	Each Party, at its own cost, shall prepare, file, prosecute and maintain Patents to cover inventions made solely by its own employees or consultants relating to Substance, the Drug
Substance, the Drug 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 21 

	 	 
Product or the Product in the Field (“Inventions”) and shall use Commercially Reasonable Efforts to file initially all such applications in and
outside the Territory. If either Party elects not to file, prosecute, or maintain any such Patent in any country, it shall give the other Party notice of this election within a reasonable period prior to allowing such Patent to lapse, become
abandoned or become unenforceable, and prior to taking any steps which would render such an Invention unpatentable and assign all rights in this Patent related to such country to the other Party allowing this other Party to file, prosecute, and
maintain this Patent in such country. 

  
 Schering shall have the right to file, prosecute and maintain Joint Patents and to determine the countries in which to file Joint Patents, provided that, in all cases, Schering shall reasonably consult and cooperate with Exhale in
connection therewith. Schering shall have the right to direct and control all material actions relating to the prosecution or maintenance of these Joint Patents in any country, including correspondence with patent authorities (Schering’s
address being named for services), interference proceedings, reexaminations, reissue, opposition and revocation proceedings. If either Party elects not to participate in any such Joint Patent or to quit its participation therein, it shall give
notice of this election to the other Party and assign all rights in this Joint Patent to the other Party allowing this Party to file, prosecute and maintain this Joint Patent as being such Party’s solely owned Patent. 
  
 Each Party shall keep the other informed of all actions taken under this
Section 11.3, and provide to the other Party all necessary declarations and cooperate with the other Party to enable Patents or Joint Patents to be issued or transferred. This Section 11.3 (a) shall survive the termination of this Agreement for any
reason. 
  

	 	(b)	The Parties agree to use Commercially Reasonable Efforts to ensure that any Patent or Joint Patent (on an Invention or Joint Invention) filed outside of the U.S. prior to filing in
the U.S. will be in a form sufficient to establish the date of original filing as a priority date for the purposes of a subsequent filing in the U.S. The Parties agree to use Commercially Reasonable Efforts to ensure that any Patent or Joint Patent
(on an Invention or Joint Invention) filed in the U.S. prior to filing outside the U.S. will be in a form sufficient to establish the date of original filing as a priority date for the purpose of a subsequent filing in any contracting state of the
Paris Convention. 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 22 

	 	(c)	License Grant. All Inventions by Schering employees or consultants and Schering’s rights in all Joint Inventions relating to the Substance, Drug Substance, Drug Product and/or
Product in the Field and the Territory shall be subject to the licenses granted to Exhale in Articles II and VI (as applicable) of this Agreement. 

  
 Exhale shall grant to Schering a royalty-free, exclusive, sub-licensable license to use these Inventions and any Patents
resulting therefrom in connection with the Product in the Field outside the Territory. Furthermore, Exhale shall grant to Schering a royalty-free, exclusive, sub-licensable license to use any Know-how generated by Exhale under this Agreement
relating to the Product in the Field in connection with the Product in the Field outside the Territory. 
  

	11.4	Enforcement Rights. 

  

	 	(a)	Notification of Infringement. If either Party learns of any infringement or threatened infringement by a Third Party of the Schering Patents or a Joint Patent, such Party shall
promptly notify the other Party and shall provide such other Party with all available evidence of such infringement. 

  

	 	(b)	Enforcement in the Territory. Subject to the next sentence, Schering shall be entitled to defend Schering Patents and Joint Patents in the Territory. Schering shall have the right,
but not the obligation, to institute, prosecute and control any action or proceeding with respect to infringement of any Schering Patents or Joint Patents covering the Development, Manufacture or Commercialization of the Product being developed or
marketed in the Territory, by counsel of its own choice. Schering shall undertake any such action concerning Schering Patents at its own expense. If such action is related to a Joint Patent, expenses shall equally be shared between the Parties.
Exhale shall have the right, at its own expense, to be represented in any action by counsel of its own choice. If Schering fails to bring an action or proceeding or otherwise take appropriate action to abate such infringement within a period of
ninety (90) days of notice by Exhale to Schering requesting action, Exhale will have the right to bring and control any such action or proceeding relating to Schering Patents by counsel of its own choice and Schering will have the right to be
represented in any such action by counsel of its own choice and at its own expense. If one Party brings any such action or proceeding, the other Party agrees to be joined as a party plaintiff if necessary to prosecute the action or proceeding and to
give the first Party commercially reasonable assistance and authority to file and prosecute the suit. Any damages or other monetary awards recovered pursuant to this Section 11.4 (b) shall be allocated first to the costs and expenses of the Party
bringing suit, then to the costs and expenses, if any, of the other Party. In the event that Exhale brings 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 23 

	 	 
such action, any amounts remaining shall be distributed as follows: compensatory damages shall be treated as Net Sales in the Territory and calendar quarter
received, and punitive and exemplary damages shall be paid sixty percent (60%) to Exhale and the remaining forty percent (40%) to Schering. In the event that Schering brings such action, sixty percent (60%) of any amounts remaining shall be payable
to Schering and the remaining forty percent (40%) to Exhale. 

  

	 	(c)	Settlement with a Third Party. The Party that controls the prosecution of a given action shall also have the right to control settlement of such action, provided however, that no
settlement shall be entered into without the written consent of the non-controlling Party if such settlement involves any payment or admission of liability by such non-controlling Party. 

  

	11.5	Defense and Settlement of Third Party Claims. If a Third Party asserts that a patent or other intangible right owned by it is infringed by the Product in the Territory, Schering
shall be entitled to solely defend against any such assertions at its cost and expense (subject to the provisions of Section 11.4 (b)), but no settlement may be entered into without the written consent of Exhale, which shall not be unreasonably
withheld. The costs for any such settlement (including, without limitation, damages, expense reimbursements, compliance, future royalties or other amounts) shall be paid fourty percent (40%) by Schering and sixty percent (60%) by Exhale. If any
Third Party is successful in any such claim and Exhale is ordered to make any payments to such Third Party in connection therewith, fifty (50%) percent of any such payments may be offset or deducted from the payment obligations of Exhale under the
Agreement. 

  

	11.6	Licenses under Third Party Patents. 

  

	 	(a)	Determination. Each Party agrees to bring to the attention of the other Party any Third Party Patent it discovers, or has discovered, and which relates to the subject matter of this
Agreement. Upon mutual agreement, the Parties may seek to obtain a license or right under one or more Third Party Patents covering any Product in the Territory in order to avoid infringement. In the event that Exhale determines that it is beneficial
for the Parties to obtain a license or right under one or more Third Party Patents covering any Product in the Territory and Schering objects to such determination within twenty (20) Business Days after such determination is made, the Parties shall
suspend action for a period of one (1) month unless a shorter period is reasonably required under the circumstances (the “Deferral Period”) to allow Schering to present its position to and discuss its position with Exhale. Such discussion
shall involve senior management of each Party. 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 24 

	 	(b)	Schering may present such facts, findings, conclusions and other information as it deems necessary to Exhale during the Deferral Period. Upon the earlier of the end of the Deferral
Period or Schering’s presentation of all of its information, Exhale shall evaluate such information and make a final determination, in its reasonable judgment, as to the desirability of obtaining a license or right under such Third Party
Patents. The decision reached by Exhale shall thereafter be final and binding on the Parties. 

  

	 	(c)	Licensing. In the event that the Parties agree to seek to obtain a license or right under any Third Party Patents or in the event of final determination by Exhale of the
desirability to obtain a license or right under any Third Party Patents, Exhale and Schering will make reasonable efforts to obtain such license or right. 

  

	 	(d)	Royalties. Any royalties and fees to be paid by Exhale to the Third Party in consideration of the license or right under the Third Party Patents with respect to the Product sold by
Exhale or its Affiliates shall be borne by Exhale but [***] ([***]%) percent of such may be deducted from the royalty otherwise payable to Schering pursuant to Article VIII of this Agreement. 

  

	11.7	Patent Expenses. All worldwide Patent Expenses with respect to Schering Patents shall be borne by Schering, subject to the terms of this Agreement; all worldwide Patent Expenses
with respect to Exhale’s Patents shall be borne by Exhale. All worldwide Patent Expenses with respect to Joint Patents shall be shared equally between the Parties. Should either Party quit its participation in a Joint Patent pursuant to Section
11.3 (a) above, the other Party acquiring such Joint Patent as being its solely owned Patent (as applicable) shall then take over all payment obligations concerning any co-inventions by employees. 

  

	11.8	Trademarks 

  

	 	(a)	Schering grants to Exhale an exclusive right to use the Trademark and Domain Name throughout the term of this Agreement and after expiration hereof (other than for Exhale’s
breach) provided, however, that Schering and Exhale shall share the Domain Name “... .com” by using a joint web page containing a link to each of the Parties individual web pages; the design of such joint web page to be discussed in and
supervised by the Development and Commercialization Committee. Exhale shall use the Trademark only for denomination of the Product in the Field in the Territory. The Parties will cooperate to find an alternative Trademark in the event that either
the FDA objects to the use of a Trademark, or the use of a Trademark in connection with the Product in the Field in the Territory potentially infringes or violates a Third Party’s rights. 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 25 

	 	(b)	Schering shall be responsible for the registration and maintenance of the Trademark which Exhale employs in connection with the marketing of the Product in the Field in the
Territory. Schering shall own and control the Trademark and bear all relevant costs relating thereto. 

  

	 	(c)	Exhale recognizes the exclusive ownership by Schering of any proprietary Schering name, logotype or Trademark furnished by Schering (including Schering’s Affiliates) for use in
connection with the marketing, sale or distribution of the Product. Exhale shall not, either while this Agreement is in effect, or at any time thereafter, register, use or challenge or assist others to challenge the Trademark or attempt to obtain
any right in or to any such name, logotype or trademarks confusingly similar to the Product as defined in this Agreement or any other goods and products, notwithstanding that such goods or products have a different use or are dissimilar to the
Product as defined in this Agreement. 

  

	 	(d)	Exhale shall not materially modify or alter the Trademark or do anything which should reasonably be expected to damage the Trademark. 

  

	 	(e)	Exhale shall promptly notify to Schering any actual alleged or threatened infringement of the Trademark or of any unfair trade practices, trade dress limitation, passing off of
counterfeit goods, or similar offenses of which it becomes aware. Only Schering will be authorized to initiate at its own discretion legal proceedings against any infringement or threatened infringement of a trademark applicable to the Product as
defined in this Agreement. Exhale shall cooperate fully in connection with Schering’s actions for the protection of the Trademark, at Schering’s expense. 

  

	11.9	Domain Names. Schering shall be responsible for the registration, hosting, maintenance and defense of the Domain Names. For the avoidance of doubt, Schering is allowed to register
in its own name, to host on its own servers, maintain and defend the Domain Names and use them for websites. 

  

	11.10 	Use of Names. Neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the
written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided however, that either Party may use the name of the other Party in any document filed with any Health Regulatory Authority, including the FDA
and the Securities and Exchange Commission, in which case Schering shall be referred to as “Schering AG, Germany”. 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 26 

 ARTICLE XII 
  
 REPRESENTATIONS AND WARRANTIES 
  

	12.1	Each of the Parties represents and warrants to the other Party as follows: 

  
 The Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms. The execution, delivery and
performance of the Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor to such party’s knowledge, violates any law or regulation of any
court, governmental body or administrative or other agency having jurisdiction over it. 
  

	12.2	Exhale hereby represents and warrants to Schering that Exhale: 

  

	 	(a)	Has employed and will in the future employ individuals of appropriate education, knowledge, and experience to conduct and oversee the conduct of the Development and
Commercialization of the Product in the Territory; 

  

	 	(b)	To the best of its knowledge, has not employed, or used a contractor or consultant that employs, any individual or entity debarred by the FDA, or, to the best knowledge of Exhale,
any individual who or entity which is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMEA), in the conduct of the pre-clinical or clinical studies of the Product; 

  

	 	(c)	There are no actions, suits, proceedings or unsatisfied judgments outstanding, including, without limitation, those that may be related to war reparations, pending or threatened
against or affecting Exhale, which may impair the ability of Exhale to perform its obligations under this Agreement, and Exhale is not aware of any existing ground on which any such action, suit or proceeding might be commenced with any reasonable
likelihood of success. 

  

	12.3	Schering hereby represents and warrants to Exhale that Schering: 

  

	 	(a)	To the best of its knowledge, has not employed, or used a contractor or consultant that employs, any individual or entity debarred by the FDA, or, to the best knowledge of Schering,
any individual who or entity which is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMEA), in the conduct of any activity relevant to the Substance, the Drug Substance or the Product; 

 

	 	(b)	Has not granted (and none of its Affiliates has granted), and during the term of this Agreement neither Schering (nor its Affiliates) will grant, 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 27 

	 	 
any right to any Affiliate or Third Party (or otherwise engage in any activity) in the Field relating to (i) the Schering Patents and/or Schering Know-how or
to the Substance, the Drug Substance, the Drug Product or the Product or (ii) any Trademark, in either case which would conflict with the rights granted to Exhale hereunder. Further, neither Schering nor any of its Affiliates will do any of the
following (and none of them has authorized or will authorize any Affiliate or Third Party to do any of the following): to sell, license or otherwise engage in any activity only relevant to any prostacyclin drug in the Field in the Territory (other
than as expressly specified in this Agreement or the Manufacturing and Supply Agreement); 

  

	 	(c)	To the best of its knowledge, (i) is the sole owner of all right, title and interest in and to the Schering Patents and the Schering Know-how; (ii) is not aware of any actual or
potential violation, infringement or misappropriation of any Third Party’s rights (or any potential claim thereof) by the Drug Substance or the Drug Product; (iii) is not aware of any material questions or challenges with respect to the
validity of the Schering Patents; (iv) is not aware of any patents or applications (other than the Schering Patents and Know-how and the Toray patent application WO98/37895) relevant to the Product in the Field in the Territory, excluding, however,
any Patents or patent applications relevant to any combination therapies involving the Product; and (v) is not aware of any information or circumstance that could materially and adversely affect the value of the Product in the Field in the Territory
(e.g., information regarding safety, efficacy, orphan drug status, or regulatory matters). 

  

	12.4	DISCLAIMER. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A WARRANTY OR REPRESENTATION, IN PARTICULAR, EXCEPT AS EXPRESSLY STATED IN
THIS AGREEMENT, NOTHING SHALL BE CONSTRUED AS: 

  

	 	(a)	A WARRANTY OR REPRESENTATION BY SCHERING AS TO THE VALIDITY OR SCOPE OF ANY SCHERING KNOW-HOW OR SCHERING PATENT OR TRADEMARK OR THAT THE EXERCISE OF THE PATENT RIGHTS WILL NOT
INFRINGE UPON THE RIGHTS OF ANY THIRD PARTY; 

  

	 	(b)	A REQUIREMENT THAT SCHERING SHALL FILE ANY PATENT APPLICATION OR TRADEMARK APPLICATION; SECURE ANY PATENT OR TRADEMARK APPLICATION, OR MAINTAIN ANY PATENT OR TRADEMARK APPLICATION
IN FORCE; 

  

	 	(c)	AN OBLIGATION BY SCHERING TO BRING OR PROSECUTE ACTIONS OR SUITS AGAINST THIRD PARTIES FOR INFRINGEMENT; 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 28 

	 	(d)	GRANTING BY IMPLICATION, ESTOPPEL, OR OTHERWISE BY SCHERING ANY LICENSES OR RIGHTS UNDER PATENTS OR KNOW-HOW OR TRADEMARK OTHER THAN AS EXPRESSLY SET FORTH IN THIS AGREEMENT;

  

	 	(e)	A REPRESENTATION OR WARRANTY BY SCHERING OF THE ACCURACY, SAFETY, OR USEFULNESS FOR ANY PURPOSE OF ANY INTELLECTUAL PROPERTY AT ANY TIME MADE AVAILABLE TO EXHALE.

  
 ARTICLE XIII 
  
 INDEMNIFICATION 
  

	13.1	Subject to Section 13.3, Exhale hereby agrees to indemnify, save, defend and hold Schering and its officers, directors, consultants, agents and employees harmless from and against
any and all suits, claims, actions, demands, liabilities, expenses and/or losses, including reasonable legal expenses and attorneys’ fees, each to the extent paid by Schering to a Third Party (collectively, “Losses” and each a
“Loss”), resulting from or arising out of Exhale or its Affiliates’ or sublicensees Development or Commercialization or Manufacture (as applicable) of the Product in the Field in the Territory except to the extent such Losses result
from or arise out of (i) the inaccuracy of any representation of Schering set forth in this Agreement; (ii) the breach of any warranty or covenant contained in this Agreement by Schering; or (iii) the negligence or willful misconduct of Schering.

  

	13.2	Schering hereby agrees to indemnify, save, defend and hold Exhale and its officers, directors, consultants, agents and employees harmless from and against any and all Losses
resulting from or arising out of (i) the inaccuracy of any representation of Schering set forth in this Agreement; (ii) the breach of any warranty or covenant contained in this Agreement by Schering; or (iii) the negligence or willful misconduct of
Schering. 

  

	13.3	Each indemnified Party agrees to give the indemnifying Party prompt written notice of any Loss or discovery of fact upon which such indemnified Party intends to base a request for
indemnification under Sections 13.1 or 13.2. Each Party shall furnish promptly to the other copies of all papers and official documents received in respect of any Loss. With respect to any Loss relating solely to the payment of money damages and
which will not result in the indemnified Party becoming subject to injunctive or other relief or otherwise adversely affecting the business of the indemnified Party in any manner, and as to which the indemnifying Party shall have acknowledged in
writing the obligation to indemnify the indemnified Party hereunder, the indemnifying Party shall have the sole right to defend, settle or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 29 

	 	 
deem appropriate. The indemnifying Party shall obtain the written consent of the indemnified Party, which shall not be unreasonably withheld or delayed,
prior to ceasing to defend, settling or otherwise disposing of any Loss if as a result thereof the indemnified Party would become subject to injunctive or other equitable relief or any remedy other than the payment of money, which payment would be
the responsibility of the indemnifying Party. The indemnifying Party shall not be liable for any settlement or other disposition of a Loss by the indemnified Party which is reached without the written consent of the indemnifying Party. The
reasonable costs and expenses, including reasonable fees and disbursements of counsel incurred by any indemnified Party in connection with any Loss, shall be reimbursed on a quarterly basis by the indemnifying Party, without prejudice to the
indemnifying Party’s right to contest the indemnified Party’s right to indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the indemnified Party.

  

	13.4	Insurance. Each Party agrees to obtain and maintain in effect a policy or policies of insurance relating to the subject of its indemnity obligations hereunder. Such policies shall
be issued by one or more reputable insurers, and shall contain reasonable terms of coverage in light of the obligations set forth above. Exhale undertakes to obtain and maintain in effect a policy or policies of insurance covering during the
Clinical Development of the Product a minimum of USD 3 Mio. per single damage, and during the Commercialization of the Product a minimum of USD 10 Mio. per single damage. Upon the request of the other Party to this Agreement, each Party shall
provide evidence of insurance coverage in compliance with this Section to the other Party. In lieu of the insurance coverage described above, Schering shall have the right to undertake a program of self-insurance to cover its indemnity obligations
hereunder, with financial protection comparable to that arranged by it for its own protection with regard to other products in its product line. 

  

	13.5	This Article XIII shall survive the termination or expiration of this Agreement. 

  
 ARTICLE XIV 
  
 TERM, TERMINATION AND CHANGE OF CONTROL 
  

	14.1	Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated as provided herein, shall continue in effect until no royalties are payable to Schering
under Article VIII hereunder. If Exhale has not within ten (10) Business Days from the execution of this Agreement by both Parties provided written proof to Schering that it has entered into an agreement with investors for at least USD 15 million of
additional funding available for the Development and Commercialization of the Product in the Field in the Territory, this Agreement shall remain null and void, and Schering shall be free to grant all rights and licenses referred to in this Agreement
to any Third Party. 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 30 

	14.2	Termination 

  

	 	(a)	Exhale may terminate the Agreement within sixty (60) days from its Pre-NDA meeting with the Health Regulatory Authority concerning the Product by advance written notice to Schering
if, as a result of this Pre-NDA meeting, Exhale determines that additional Phase 3 Clinical Trials beyond those conducted prior to the date hereof will be required for Regulatory Approval of the Product in the Field by the Health Regulatory
Authority. 

  

	 	(b)	Failure of Exhale or Schering to comply with any of their respective material obligations contained in this Agreement which constitutes a material breach (e.g. on the part of
Exhale, its obligation to pursue the Development Plan pursuant to Section 3.1 (b) and (c) above or the Commercialization Plan pursuant to Section 4.2 and 4.3 above), shall entitle the other Party to give the Party a default notice requiring it to
cure such default. If such default is not cured within ninety (90) days after receipt of such notice, the notifying Party shall be entitled (without prejudice to any of its other rights conferred on it by this Agreement) to terminate this Agreement.
Notwithstanding the foregoing, in the event of a non-monetary default, if the default is not reasonably capable of being cured within the ninety (90) day cure period by the defaulting Party and such defaulting Party is making a good faith effort to
cure such default, the notifying Party may not terminate this Agreement, provided however, that the notifying Party may terminate this Agreement if such default is not cured within one hundred eighty (180) days of such original notice of default.
The right of either Party to terminate this Agreement as herein above provided shall not be affected in any way by its waiver of, or failure to take action with respect to any previous default. 

  

	 	(c)	In the event that one of the Parties hereto shall go into liquidation, a receiver or a trustee be appointed for the property or estate of that Party and said receiver or trustee is
not removed within one hundred twenty (120) days, or the Party makes an assignment for the benefit of creditors, and whether any of the aforesaid bankruptcy events be the outcome of the voluntary act of that Party, or otherwise, the other Party
shall be entitled to terminate this Agreement. 

  

	 	(d)	In the event that this Agreement is terminated by Exhale in accordance with Section 14.2(a) or by either Party in accordance with Sections 14.2(b) or (c) hereof, Exhale will: (i)
deliver to Schering the Schering Know-How and assign to Schering its rights in said Schering Know-How, Schering Patents, Trademarks and Domain Names if any; (ii) not use the Schering Know-How as long as it has to be kept confidential pursuant to
Article X hereof; (iii) not infringe any of the Schering 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 31 

	 	 
Patents; (iv) make all payments accrued under this Agreement prior to the effective termination date; (v) transfer all regulatory filings and approvals and
all Orphan Drug Act petitions, designations and exclusivity related to the Product, to Schering upon Schering’s written request for same; (vi) refrain from filing an ANDA for a generic of the Product; and (vii) sell to Schering, at any time
within ninety (90) days of such termination, all or any portion of the inventory of the Substance, the Drug Substance, the Drug Product and/or the Product owned by Exhale or its Affiliates which are intended for sale in the Territory at a price
equal to Exhale’s or its Affiliate’s fully burdened costs for such inventory. If Exhale has terminated the Agreement pursuant to Section 14.2(b) above, Schering shall be obligated to purchase such inventory. Otherwise, Exhale shall only
sell and Schering shall only purchase all or any portion of the inventory at Schering’s election. Such election shall be made by Schering in writing in a notice to Exhale, and within thirty (30) days of such termination. If Schering purchases
such Exhale inventory, Exhale shall ship at Schering’s cost and direction such inventory to Schering. Schering shall pay for such inventory in advance of receipt of such inventory. 

  

	 	(e)	Each Party agrees (to the extent that it may lawfully do so) that it will not at any time insist upon, or plead, or in any manner whatsoever claim to take the benefit or advantage
of, any stay or extension law or any other law wherever enacted, now or at any time hereinafter in force, which would prohibit the termination of this Agreement by the other Party as provided in this Agreement, in any way modify the effects of
termination by such Party as provided in this Agreement, or prohibit or impede the exercise by such Party of any other rights set forth in this Article XIV or elsewhere in this Agreement. Each Party (to the extent it may lawfully do so) hereby
expressly waives all benefit and advantage of any such law and covenants that it will not hinder, delay or impede the execution of any power granted to the other Party in this Agreement, but will permit the execution by such Party of every power
granted to such Party in this Agreement as though such law had not been enacted. 

  

	 	(f)	In the event that Exhale intends to pursue potential transactions as a result of which (i) the majority of the outstanding voting securities or substantially all of the assets or
business of Exhale would become owned by a pharmaceutical company that sells a pulmonary hypertension drug that is directly competitive with the Product (a “Competitor Pharmaceutical Company”) that did not own a majority of the voting
securities of Exhale as of the Effective Date; or (ii) the actual power to direct or cause the direction of the management and policies of Exhale through ownership of the outstanding voting securities would become vested in a Competitor
Pharmaceutical Company that did not possess such power as of the Effective Date (hereinafter collectively the “Change of Control Event”), Schering will have the option to 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 32 

	 	 
exercise an exclusive right of first negotiation to acquire Exhale as described below (the “Option”). Before entering a transaction with any Third
Party which would result in a Change of Control Event, Exhale shall notify Schering that it may pursue such potential transactions and Schering shall have ten (10) Business Days from the date of such notice to provide Exhale written notice that it
has exercised its Option. If Schering does not provide written notice that it has exercised its Option within such ten (10) Business Day period, then Exhale shall have no further obligation with respect to the Option and shall be free to negotiate
and enter into any transaction which results in a Change of Control Event with any Third Party. If Schering properly exercises the Option as described above, then the Parties shall negotiate reasonably and in good faith concerning the acquisition of
Exhale by Schering for a period of forty-five (45) days. If the parties do not execute and deliver an agreement for the acquisition of Exhale by Schering within such forty-five (45) days’ period, then Exhale shall be free to negotiate and enter
into any transaction which results in a Change of Control Event with any Third Party; provided that if such Third Party transaction is, when taken as a whole, materially and substantially less favorable to Exhale than the terms last offered to
Exhale by Schering, then Exhale will offer Schering such transaction for a period of ten (10) days before entering such transaction with a Third Party. 

  

	 	(g)	Except where expressly provided for otherwise in this Agreement, termination or expiration of this Agreement shall not relieve the Parties hereto of any liability, including any
obligation to make payments hereunder, which accrued hereunder prior to the effective date of such termination or expiration, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect
to any breach of this Agreement nor prejudice any Party’s right to obtain performance of any obligation. 

  

	14.3	Surviving Rights. The rights and obligations set forth in this Agreement shall extend beyond the termination of the Agreement only to the extent expressly provided for herein as
follows: Sections 6.6 and 8.4, Article IX, Article X, the last sentence of Section 11.1, Sections 11.3(a), and (c), 11.8(a), 11.10, and 12.4, Article XIII, Sections 14.2(d), (e) and (g), 14.3 and Article XV. 

  
 ARTICLE XV 
  
 MISCELLANEOUS 
  

	15.1	Assignment. 

  

	 	(a)	Subject to compliance with Section 14.2 (f) above, either party may assign any of its rights or obligations under this Agreement to any of its Affiliates or to a successor to all or
substantially all of such party’s 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 33 

	 	 
business or assets; provided, however, that such assignment shall not relieve such party of its responsibilities for performance of its obligations under
this Agreement. Except as provided herein, neither Party to this Agreement shall have the right to assign its rights or obligations under this Agreement. 

  

	 	(b)	This Agreement shall be binding upon and inure to the benefit of the permitted assigns of the Parties. Any purported assignment not in accordance with this Agreement shall be void.

  

	15.2	Force Majeure. Neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses on account of failure of performance by the defaulting Party if
the failure is occasioned by government action, war, fire, explosion, flood, strike, lockout, embargo, act of God or any other cause beyond the reasonable control of the defaulting Party, provided that the Party claiming force majeure has extended
reasonable efforts to avoid or remedy any such force majeure, continues to employ such efforts and promptly notifies the other Party of such force majeure event. 

  

	15.3	Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts, as may be necessary or appropriate in order to carry
out the purposes and intent of this Agreement. 

  

	15.4	No Trademark Rights. Except as otherwise provided herein, no right, express or implied, is granted by this Agreement to use in any manner the names “Exhale” or
“Schering” or any other trade name or trademark of the other Party or its Affiliates in connection with the performance of this Agreement. 

  

	15.5	Notices. All notices hereunder shall be in writing, effective upon receipt, and shall be delivered personally, mailed by registered or certified mail (return receipt requested,
postage prepaid), or sent by express courier service, to the other Party at the following addresses (or at such other address for a Party as shall be specified by like notice): 

  

	 	(a)	If to Exhale: 

  
 1301 Shoreway Road 
 Suite 320 
 Belmont, California 
 94002, U.S.A.

  

	 	(b)	If to Schering: 

  
 Schering AG 
 Attn. Dr. Bernhard Fritz-Zieroth

 Muellerstraße 178 
 D-13353 Berlin 
 Germany 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 34 

 With copy to: 
  

Schering AG 
 Legal Department 

Muellerstraße 178 
 D-13353 Berlin

 Germany 
  

	15.6	Waiver. Except as specifically provided herein, the waiver from time to time by either of the Parties of any of their rights or their failure to exercise any right or remedy shall
not operate or be construed as a continuing waiver of same or of any other of such Party’s rights or remedies provided in this Agreement. 

  

	15.7	Severability. Each Party hereby agrees that it does not intend, by its execution hereof, to violate any public policies, statutory or common laws, rules, regulations, treaties or
decisions of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become invalid, the Parties hereto shall substitute, by mutual consent, valid
provisions for such invalid provisions, which valid provisions in their economic and other effects are sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such
valid provisions. In case such valid provisions cannot be agreed upon, the invalidity of one or several provisions of this Agreement shall not affect the validity of this Agreement as a whole or the validity of any portions hereof, unless the
invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid provision. 

  

	15.8	Ambiguities. The Parties acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its
revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall be construed
fairly as to the Parties hereto and not in favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement. 

  

	15.9	Governing Law and Place of Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws in force in the State of New York, U.S., without giving effect
to the choice of laws provisions thereof. Any legal action arising under this Agreement shall be instituted in the state or U.S. district Courts for the Southern District of New York and each Party consents to the jurisdiction of such courts for the
purposes of any such action. 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 35 

	15.10 	Headings. The Section and Paragraph headings contained herein are for the purposes of convenience only and are not intended to define or limit the contents of said Sections or
Paragraphs. 

  

	15.11 	Counterparts. This Agreement may be executed by the Parties in one or more counterparts. Such counterparts may be exchanged by facsimile (provided that each executed counterpart is
transmitted in one complete transmission). Where there is an exchange of executed counterparts, each Party shall be bound by this Agreement notwithstanding that original copies of this Agreement may not be exchanged immediately. The Parties shall
cooperate after execution of this Agreement and exchange by facsimile to ensure that each Party obtains an original, executed copy of this Agreement. 

  

	15.12 	Entire Agreement; Amendments. This Agreement, including all Schedules attached hereto, all documents and things incorporated herein by reference and all of the documents delivered
concurrently herewith set forth all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersede and terminate all prior agreements and understandings between the Parties.
No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 

  

	15.13 	Expenses. Except as otherwise specified in this Agreement, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisers and
accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party incurring such costs and expenses. 

  

	15.14 	Independent Contractors. The status of the Parties under this Agreement shall be that of independent contractors. Neither Party shall have the right to enter into any agreements on
behalf of the other Party, nor shall it represent to any person that it has any such right or authority. Nothing in this Agreement shall be construed as establishing a partnership or joint venture relationship between the Parties.

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 36 

 IN WITNESS WHEREOF, Exhale and Schering have caused this Agreement to be executed as of October 2, 2003
by their respective duly authorized representatives. 
  

											
	 SCHERING AKTIENGESELLSCHAFT
	 	 	 	 EXHALE THERAPEUTICS, INC.

					
	 Date: October 2, 2003
	 	 	 	 	 	 	 	 Date: October 2, 2003

					
	 /s/ B. Putz
	 	 	 	 /s/ Ulrich Koch
	 	 	 	 /s/ Donald J. Santel

	 Dr. Barbara Putz
	 	 	 	 Dr. Ulrich Koch
	 	 	 	 Name:
	 	 DONALD J. SANTEL

	 Head CCD 5TH Eur.
	 	 	 	 Head Corp. Bus. Dev.
	 	 	 	 Title:
	 	 PRESIDENT & CEO

  
 Schedules: 
  

	1.	List of Schering Patents 

  

	2.	Development Plan 

  

	3.	Commercialization Plan 

  

	4.	Specifications of Drug Product and Drug Substance 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 37 

 Schedule 1 
 to Exhale Agreement 
  

 List of Schering Patents 
  

	1.	Product Patent No. US 4,692,464; 

  

	2.	Process Patent No. US 4,894,336; 

  

	3.	Process Patent No. US 5,200,530. 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 2 
 to Exhale Agreement 
  

 Exhale Therapeutics 
 Development Plan for Ventavis® (Iloprost) 
  
 Registration
Strategy 
  

	 	•	Establish FDA Division of Cardio-Renal Drug Products as the reviewing division for Iloprost Inhalation Solution, and have a pre-IND meeting with the Division at the earliest time
to obtain agreement for the registration strategy 

  

	 	•	File IND with Schering pre-clinical, CMC and clinical data with protocols for Phase 1 QT study (if needed) and Phase 3 iloprost add on study (if needed)

  

	 	•	Request an end-of-Phase 2 meeting with FDA to obtain agreement on completeness of existing clinical data for approval 

  

	 	•	Initiate a second Phase 3 pivotal trial if the Agency clearly states (at either the pre-IND meeting or the end-of-Phase 2 meeting) that the existing clinical data is not adequate
for filing. This trial would serve as a back-up to the Tracleer study if significance is not reached in that trial. 

  

	 	•	Submit NDA based on European submission with additional clinical analyses to support labeling for Stage III and IV Pulmonary Arterial Hypertension (PAH) as long term goal; short
term goal could be approval for PPH stage III and label extension to PAH stages III and IV by ongoing clinical studies (e.g. iloprost add-on study) 

  

	 	•	File Orphan application to achieve additional marketing exclusivity 

  
 Introduction 
  
 The Division of Cardio-Renal Drug Products has reviewed all 3 currently available drugs for pulmonary hypertension (Flolan®, Tracleer®, and Remodulin®). To date, there has been no interaction with that division concerning Iloprost Inhalation Solution. Berlex, the Schering subsidiary in the US, conducted an End of Phase II meeting in
July 1999 with the Division of Gastrointestinal and Coagulation Drug Products. 
  
 Exhale plans to meet with the Division of Cardio-Renal Drug Products as soon as possible (mid-November) in a pre-IND meeting to discuss the pre-clinical and CMC information required for initiating clinical trials in the U.S. The potential
need to conduct an additional Phase I study will be discussed - a study to assess the effect of iloprost on the QT interval (a recent proposed requirement for all new chemical entities). We are also planning to conduct a iloprost add-on study under
the IND. See Attachment 1 for a list of clinical studies. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 2 
 to Exhale Agreement 
  

 We will state that we contemplate no additional trials, other than the Phase I trial (if needed) and ask if the
Division thinks this is a reasonable approach. In this way, we will be able to obtain early feedback on the FDA’s view of the completeness of the available data package, which will be submitted in the IND. 
  
 As discussed with Dr. Ray Lipicky, the former head of the Cardio-Renal Division, at the
pre-IND meeting we will propose that an End of Phase II meeting be held early next year (prior to the completion of the QT study) to discuss submitting the NDA based on the European marketing application (MAA). 
  
 Preclinical 
  
 A full complement of preclinical pharmacology and toxicology studies of iloprost (administered by parenteral and oral dosing in a variety of
species) will be submitted in the IND, along with a 6 month inhalation toxicity study in rats conducted by Schering. The NDA may require a 28-day inhalation study in dogs sponsored by Exhale, if the FDA believes that such a study is necessary.

  
 Clinical Pharmacology 
  
 The pharmacokinetic data for iloprost given by inhalation are limited to a single Phase I
crossover study of 3 nebulizers in 12 patients. No pharmacokinetic data were obtained in the Phase III study. 
  
 At the End of Phase II meeting with the GI/Coagulation Division on 7/99, the FDA representatives noted that dose-blood level data should be provided in order to evaluate systemic side effects. According to Schering
personnel, further discussion on this point centered on the conduct of a pharmacokinetic/pharmacodynamic study linking the inhaled formulation to iloprost given intravenously. 
  
 We will provide a strong justification that this study is not necessary for the following reasons: 
  

	 	•	The Exhale drug product will be identical to the Schering drug product, supplied by the Schering facility in Spain. Schering will continue to manufacture the drug substance and drug
product, so there are no CMC changes from the EMEA submission. 

  

	 	•	In the Phase III study, doses of iloprost were titrated upwards (to a top dose of 5 μg 9 times daily) as tolerated by each patient individually. This is similar to the
up-titration utilized for both Flolan and Remodulin. Systemic concentrations of iloprost have no role in this individualized dosing. 

  

	 	•	Extensive pharmacokinetic information is available for Schering’s intravenous iloprost product administered for the treatment of peripheral 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 2 
 to Exhale Agreement 
  

	 	 
arterial obstructive disease. Furthermore, robust pharmacokinetic data was obtained from the Phase I crossover study with inhaled iloprost, albeit limited to
a single dose of 5 μg. These data show area under the curve (AUC) concentrations of approximately 50 pg h/ml. This value is approximately half of the AUC obtained after a 2 ng/kg/min intravenous dose which is commonly used for peripheral
arterial obstructive disease. 

  
 Potential QT interval study

  
 A “Preliminary Concept Paper” was issued by the FDA in November
2002 that outlined the proposed requirement for rigorous characterization of the effects of a new chemical entity on the QT interval (to assess the potential to affect cardiac repolarization and certain types of arrhythmias). We will review the ECG
data generated by Schering AG in support of iloprost given by both inhalation and intravenous infusion. However, it is likely that this dataset will be inadequate to convince the FDA that we have fully characterized the effect of iloprost on cardiac
repolarization as no positive control was included. Therefore, we will be prepared to conduct a well-standardized study (with both positive and placebo control) to assess this. 
  
 Clinical 
  
 The clinical program consisted of three controlled studies (Phase I crossover, Phase II, and Phase III), long-term open label extensions of the Phase II and III studies,
and additional supportive safety data from intravenous iloprost use in about 7000 patients, including 155 patients with pulmonary hypertension. This data will be filed with the IND (allowing adequate review time by the Agency) and will serve as
basis of the clinical section of the NDA. Additional analyses will be performed to support the proposed labeling (see below). 
  
 A) Rationale for Adequacy of Single Pivotal Trial 
  
 We believe that there is a reasonable chance that the single completed pivotal trial will be sufficient for FDA review and approval, based on the following: 

 

	 	•	At the End of Phase II meeting held with Berlex, the FDA noted that a single pivotal trial would be adequate if the results were consistent and persuasive. 

 

	 	•	The efficacy data from the pivotal trial are robust (solid p values using several statistical methods) and persuasive (internally consistent across multiple endpoints).

  

	 	•	The results are also consistent across the treatment sites and subgroups (with the exception of chronic thromboembolic disease; see next bullet). 

  

	 	•	The CPMP gave a positive opinion for iloprost based on the single pivotal trial. 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 2 
 to Exhale Agreement 
  

 B) Iloprost add-on study 
  
 At the pre-IND meeting, we will get a sense of the FDA’s feedback on the adequacy of the dataset. In the event that the FDA insists
that a second pivotal study is necessary prior to filing the NDA, we will be prepared to discuss with them the adequacy of using data from an iloprost add-on trial to serve as that second pivotal. The planned add-on trial will be a Phase 3
placebo-controlled study of iloprost added to common therapy including approved disease specific therapies such as Tracleer in patients who are inadequately controlled on Tracleer alone. Pilot experience of iloprost add-on therapy in patients
already treated with Tracleer will form a basis for the final study design. Importantly, we plan to initiate this study in March 2004 for the following reasons: 
  

	 	•	This study will serve as a contingency study in the event the FDA insists upon a second pivotal study, either during the pre-IND meeting or during the end of Phase II meeting.

  

	 	•	The concept of an add-on therapy is well supported by the differing mechanisms of action. 

  

	 	•	Two recently published studies (BREATHE-2 and Hoeper 2003) support the concept of additive effects for Tracleer and a prostacyclin. Therefore, pilot experience of an iloprost add-on
therapy in patients already on bosentan might further facilitate the design of an add-on study. 

  

	 	•	Efficacy and safety data on the combination is important for profiling iloprost in this age of evidence-based medicine 

  

	 	•	This will give important opinion leaders a chance to use the drug in a clinical trial setting prior to launch. 

  
 C) Repeat pivotal placebo-controlled study 
  
 If at the pre-IND meeting or the end-of-phase 2 meeting the FDA insists that a second
confirmatory placebo-controlled pivotal trial similar to the pivotal trial (AIR study published by Olschewski in the NEJM) is required, we will initiate such a placebo-controlled trial in PAH patients . This study will be a contingency study in the
event that the iloprost add-on study results are not robust enough to serve as a second pivotal trial. A placebo-controlled study in PAH patients who are not taking other disease targeting drug such as Tracleer has a lower risk of failing to
achieving a significant p value, but will require a much longer period of time to recruit. This is due to the competition for newly diagnosed patients to be recruited into ongoing or planned clinical trials for the oral agents ambrisentan,
sitaxsentan, or sildenafil. The option of using international sites except Europe will also be fully explored. Assuming that the iloprost add-on study yields positive results sufficient for NDA approval, the repeat placebo-controlled trial will be
closed to further recruitment, and all patients will be offered open-label iloprost. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 2 
 to Exhale Agreement 
  

 D) Support for labeling of Stage III and IV Pulmonary Arterial Hypertension 
  
 Schering AG obtained an EMEA approval based on the efficacy data obtained from the pivotal
Phase III study. However, the CPMP restricted the labeling to NYHA Class III patients with Primary Pulmonary Hypertension. 
  
 Although the pivotal study enrolled Class III and IV patients, the restriction to Class III patients was based on the opinion that the Class IV patients (mean walk
distance 270 meters) had milder disease than typical Class IV patients seen by clinicians. This restriction is similar to that applied to Tracleer in Europe (Remodulin is not approved in Europe); the CPMP believes that Class IV patients should be
treated with Flolan. We will justify that the labeling for Iloprost Inhalation Solution should include both Class III and Class IV because the latter were well represented in the Phase III study (approximately half the patients) and showed a similar
response to the drug. This strategy follows the precedent set by the FDA with both Tracleer and Remodulin. 
  
 The European restriction to Primary Pulmonary Hypertension is based on the data in the Phase III patients (approximately half) who had pulmonary hypertension secondary to chronic thromboembolic disease (CTED),
collagen vascular disease, or appetite suppressants. The results for the 6 minute walk distance were not statistically significant for this secondary PH subgroup as a whole. However, we will assert that Iloprost Inhalation Solution should be
approved for primary arterial hypertension (PAH) (which includes primary PH and secondary PH but excludes CTED) for the following reasons: 
  

	 	•	CTED is a different pathophysiologic group, according to the most recent WHO classification system. In the Phase III study, these patients tended to be older with a longer duration
of disease. The efficacy of vasodilator in this subgroup has never been shown in a controlled trial. 

  

	 	•	The efficacy of iloprost for PAH (total patient group excluding CTED) is well supported by the Phase III data. 

  

	 	•	Tracleer and Remodulin were both approved for pulmonary hypertension and not restricted to PPH despite having that group dominate the demographics. 

  
 In case of receiving the PPH indication alone, Exhale will conduct a post-marketing study to
gain the PAH indication. Exhale’s focus is to obtain agreement on the labeling strategy as early as possible. 
  
 CMC 
  
 Drug substance will be manufactured and provided by Schering AG under a separate commercial supply agreement using a European-approved manufacturing procedure. Schering will file a DMF containing all CMC information,
including drug product and all stability data that was filed in their 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 2 
 to Exhale Agreement 
  

 
MAA. The drug product will also be manufactured by Schering in their Madrid facility through at least approval and launch. A US-based company has been
identified and could be qualified as a second drug product manufacturer shortly after launch. 
  
 The IND will reference the Schering DMF for the drug substance and contain information drug product manufacturing procedures and specifications, along with aerosol characterization data obtained by Schering using the
HaloLite and ProDose nebulizers. A 510k application has been filed by the manufacturer of the ProDose nebulizer and is expected to get approved by Oct. 2003. 
  
 Orphan application 
  
 Exhale will file an Orphan Drug Designation Request (similar to that obtained for iloprost in the EU), which will support 7 years of marketing exclusivity. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 2 
 to Exhale Agreement 
  

					
	Attachment 1	 	Iloprost Clinical Plan	 	September 11, 2003

  

													
	 Protocol
Number/
Phase

	  	 Study
 Description

	  	 No.
 Subjects

	  	 Endpoints

	  	 Est. Cost

	  	 Target Dates
for Start and
Data Avail.

	  	 Status

	Pilot Ventavis/Tra cleer combination study	  	Iloprost add-on to Tracleer study	  	 	  	Clinical effects: 6 minute walk distance and other useful variables, first hints for safety/tolerability	  	 	  	 	  	 •      Pilot study as basis for iloprost add-on study

							
	E200-TBD	  	 QT Interval Assessment
 (if needed)
	  	N = ~120	  	QT interval	  	$2.5M	  	 Start Apr 04
 Data Sep 04
	  	 •      Need for study contingent on FDA discussions at pre-IND meeting

							
	E200-002 Phase II/III	  	 Tracleer Add-on; Iloprost vs. Placebo added to Tracleer;
 12 weeks Rx
	  	 N = 140
 (75 per Rx)
	  	6 minute walk distance plus usual secondary endpoints; Echo/Doppler	  	$4.5M	  	 Start Mar 04
 Data Mar
05
	  	 •      Contingency study to serve as second pivotal if required by
FDA
  
 •      Will provide important use data for U.S. marketing

							
	E200-004 Phase III	  	 Repeat Pivotal (Iloprost vs. Placebo);
 12 weeks
Rx
	  	 N=190
 (95 per Rx)
	  	6 minute walk distance plus usual secondary endpoints	  	$5 M	  	 Start Apr 04
 Data Jan 06
	  	 •      Back-up to iloprost Add-on study, if FDA requires second pivotal

							
	E200-TBD Phase II	  	 Viagra Pilot; Iloprost frequency – 3X/day, 4X/day, 6X/day;
 4 weeks Rx
	  	 N = 45
 (15 per Rx)
	  	6 minute walk distance	  	$750K	  	 Start TBD
 Data 9 mos
	  	 •      Study start post NDA submission

							
	E200-TBD Phase II	  	IPF pilot Iloprost vs. Placebo in addition to	  	 N = 40
 (20 per Rx)
	  	Integrated 6 min walk with oxygen saturation	  	$750K	  	 Start TBD
 Data 12 mos
	  	 •      Study start post NDA submission

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 7 

 Schedule 2 
 to Exhale Agreement 
  

													
	 Protocol
Number/
Phase

	  	 Study
Description

	  	 No.
 Subjects

	  	 Endpoints

	  	 Est. Cost

	  	 Target Dates
for Start and
Data Avail.

	  	 Status

	 	  	 standard care;
 4 weeks Rx
	  	 	  	 	  	 	  	 	  	 
							
	 E200-TBD
 Phase III
	  	Viagra confirmatory; Viagra plus Iloprost at frequency from pilot study vs. Placebo; 12 weeks Rx	  	N = 140 (70 per Rx)	  	6 min walk distance	  	$4M	  	Start TBD Data 20 mos	  	 •      Study contingent on data from pilot study

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 8 

 Schedule 3 to 
 Exhale Agreement 
  

 Exhale Therapeutics 
 Commercialization Plan for Ventavis® (Iloprost) 
  
 Executive Summary 
  
 Ventavis will be positioned in the US as
the preferred prostacyclin for the treatment of Pulmonary Arterial Hypertension (PAH) in a market that is projected to grow to over [***] million per annum by 2008. There is considerable enthusiasm among physicians and patients for Ventavis, to be
used either alone or in combination with other agents, as an effective and safe inhaled prostacyclin to manage symptom control, improve exercise tolerance, improve the quality of life and potentially prolong the lives of those suffering from PAH.

  
 Exhale will build a commercial team to conduct pre-launch market development
activities and execute a launch campaign that will insure rapid adoption and success of Ventavis in the US. At launch, a “1-800-Ventavis Access Hotline” will provide reimbursement support and 24 hour Ventavis patient support. The Ventavis
hotline and distribution will be managed via a closed distribution through specialty pharmacy partners, which will provide ongoing care for Ventavis patients. 
  

Post Ventavis launch, Exhale will expand the PAH market opportunity through education by increasing the number of pulmonologists diagnosing and treating PAH patients,
as well as encouraging other medical specialties to be involved in early diagnosis of PAH. The 5 year peak revenue forecast for Ventavis in the US is conservatively set at [***] million, requiring approximately [***] patients or [***]% of the
current US PAH patient base. Ventavis is poised for success in the US market. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 3 to 
 Exhale Agreement 
  

 Market Dynamics 
  
 The US prevalence of PAH is approximately 50,000. Of these patients, approximately 25 % (12,500) have primary disease and 75 % (37,500) have secondary disease. The number
of diagnosed and treated and patients at the beginning of 2003 was approximately 15,000. This number doubled in 2002 due to the availability of new therapies and pharmaceutical manufacturer sponsored education and promotion. Physicians diagnosing
and treating PAH patients also increased. The number of physicians treating PAH patients is relatively small with 80 % of PAH patients being managed by less than 200 physicians (“high prescribers”). There are approximately 6,000 practicing
pulmonologists in the U.S. 
  
 The majority (80%) of currently diagnosed and
treated PAH patients are late stage (Class III/IV). However, the availability of new treatments and education are projected to improve early diagnosis and increase the diagnosed prevalence to nearly 22,000 patients by 2008. The current value of the
US market for PAH is approximately $400 million in 2003, and is projected to grow to $750 million by 2008. Actelion, Tracleer (bosentan), is the only company with a dedicated field sales force, with over 40 representatives involved in education and
promotion. 
  
 Combination therapy is becoming standard of care within the PAH
market. Throughout their lifetime, following diagnosis, most PAH patients will be on a combination of anticoagulants, digoxin, diuretics, calcium channel blockers, endothelin antagonists, and prostacyclins. Most therapies for mild to moderate PAH
patients are oral. However, the currently available prostacyclins, Flolan (epoprostenol) from GSK and Remodulin (treprostinil) from United Therapeutics require intravenous and subcutaneous administration respectively. These agents are therefore
reserved for the more severe PAH patients. 
  
 The average cost per year for the
branded agents is: Tracleer ($28,000), Remodulin ($55,000 – $80,000), and Flolan ($55,000-$80,000). Due to the orphan classification, the life threatening nature of PAH and the paucity of agents to treat the disease, reimbursement is favorable,
with the majority patients having either commercial, federal, or state coverage for medications. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 3 to 
 Exhale Agreement 
  

 Exhale Sales Organization 
  
 Exhale plans to launch Ventavis with a U.S. field based selling team of 12 pulmonary representatives, 1 sales director, and 1 national
accounts manager. Each of the 12 pulmonary sales representatives will be responsible for approximately 16 “high prescribers” at launch, and additional “high potential” prescribers for PAH market development activity. 

 
 Exhale has conducted extensive analysis of the U.S. pulmonary market using IMS
prescription data and ICD diagnosis codes (ProMetrics - Philadelphia, PA) for field sales based territory creation, alignment, and optimization. Exhale currently has market maximization maps by representative placement in the U.S. for the PAH market
utilizing 4 scenarios: 12, 24, 36, and 48 field based representatives. 
  
 As
Ventavis launches and market development activity expands the prescriber base for PAH therapies, Exhale will expand the field selling force in groups of 12 as needed to efficiently manage Rx growth, while minimizing disruption to the field selling
effort. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 3 to 
 Exhale Agreement 
  

 Strategic Imperatives 
  

	 	•	100% Pre-Launch Awareness 

  

	 	•	Pulmonologists 

  

	 	•	Cardiologists 

  

	 	•	PAH Patients 

  

	 	•	Payors 

  

	 	•	Advocacy Support 

  

	 	•	Key Opinion Leader Support 

  

	 	•	PHA Support 

  

	 	•	Universal Reimbursement Coverage 

  

	 	•	Private payors 

  

	 	•	State payors 

  

	 	•	Federal payors 

  

	 	•	Patient-Friendly Product Support and Distribution 

  

	 	•	Ventavis “800” Access Hotline 

  

	 	•	Specialty Pharmacy Partner Distribution Network 

  

	 	•	Priority Health Care Pharmacy 

  

	 	•	Care Mark Pharmacy 

  

	 	•	Nova Factor Pharmacy 

  

	 	•	Product Positioning: 

  

	 	•	“Ventavis represents an advance in treatment of patients with pulmonary arterial hypertension. The unsurpassed efficacy, pulmonary targeted delivery, ease of administration,
and decreased systemic adverse events associated with systemically delivered prostacyclins make Ventavis the first line prostacylin for pulmonary arterial hypertension patients, as monotherapy or in combination with ETR Antagonists and/or PDE 5
Inhibitors” 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 3 to 
 Exhale Agreement 
  

 Pre-Launch Tactics 
  

	 	•	Patient Awareness 

  

	 	•	PHA 

  

	 	•	Advocacy Development 

  

	 	•	Conventions 

  

	 	•	CHEST Scientific Exhibit Booth 

  

	 	•	American Thoracic Society Scientific Exhibit Booth 

  

	 	•	American College of Cardiology Scientific Exhibit Booth 

  

	 	•	Pulmonary Hypertension Association Scientific Exhibit Booth 

  

	 	•	Continuing Medical Education 

  

	 	•	Monograph on PAH and Emerging Therapies 

  

	 	•	Patient Education 

  

	 	•	Key Opinion Leader Development 

  

	 	•	Education 

  

	 	•	Speaker Preparation and Training 

  

	 	•	Reimbursement Coverage Initiatives 

  

	 	•	American Hospital Formulary Service Monograph 

  

	 	•	Commercial Payor Presentations 

  

	 	•	State and Federal Payor Presentations 

  

	 	•	Specialty Pharmacy Distribution Network* 

  

	 	•	Priority Health Care / Caremark / NovaFactor 

  

	 	•	800 Access Hotline 

  

	 	•	Reimbursement Assistance 

  

	 	•	Patient Training 

  

	 	•	24 Hour Patient Care Assistance 

  

	 	•	Inventory Management 

  

	 	•	Data Management 

  

	 	•	National Sales and Marketing Team Development 

  

	 	•	Chief Commercial Officer 

  

	 	•	Marketing Director 

  

	 	•	Marketing Manager 

  

	 	•	National Accounts Director 

  

	 	•	Sales Director 

  

	 	•	12 Pulmonary Specialist Representatives 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 3 to 
 Exhale Agreement 
  

 Launch Tactics 
  

	 	•	Ventavis Commercial Team Headcount 

  

	 	•	3 Marketing and Management 

  

	 	•	14 Sales and Management 

  

	 	•	Conventions 

  

	 	•	CHEST Mail Drop at Physicians’ hotel rooms (2003) 

  

	 	•	CHEST Scientific Promotional Booth (2004 and beyond) 

  

	 	•	American Thoracic Society Promotional Booth 

  

	 	•	American College of Cardiology Promotional Booth 

  

	 	•	Pulmonary Hypertension Association Booth 

  

	 	•	Ventavis Promotional Pieces 

  

	 	•	Detail Aids 

  

	 	•	Sell Sheet 

  

	 	•	Slim Jim 

  

	 	•	Reprints 

  

	 	•	Journal Ads 

  

	 	•	CHEST 

  

	 	•	AJRCCM 

  

	 	•	JACC 

  

	 	•	Continuing Medical Education 

  

	 	•	CHEST Meeting CME Symposia 

  

	 	•	ATS Meeting CME Symposia 

  

	 	•	Ventavis National Consultants / Speaker Training Meetings 

  

	 	•	100 Pulmonologists 

  

	 	•	Ventavis Community Advisory Panel Programs 

  

	 	•	250 Pulmonologists 

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 3 to 
 Exhale Agreement 
  

	*	Specialty pharmacies in the US such as Priority Healthcare, Novafactor, and Caremark currently manage patients on agents such as Flolan (GSK), Remodulin (United Therapeutics), and
Tracleer (Actelion). These specialty pharmacies provide support to healthcare practitioners and also complete patient care including reimbursement services, disease specific training, product specific training, and ongoing support for patients under
their care. In addition to improved care for patients on their respective pharmaceutical products, pharmaceutical manufacturers, like Exhale, also benefit from this type of closed distribution network through access to patient and physician specific
data and through product inventory control. Many US pharmaceutical companies that distribute biologic agents with special storage needs or that sell to special patient populations use the services of specialty pharmacy distribution partners. For
more information please refer to: 

  
 http://www.accredohealth.net/nova/ 
 http://www.priorityhealthcare.com 
 http://www.rxpower.com/caremark.html 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 Schedule 3 to 
 Exhale Agreement 
  

 Revenue Forecast 
  

													
	 Year

	  	2006

	  	2007

	  	2008

	  	2009

	 $ (millions)
	  	$	[***]	  	$	[***]	  	$	[***]	  	$	[***]
	 Patients
	  	 	[***]	  	 	[***]	  	 	[***]	  	 	[***]

  
 Pre-Launch Development and Launch
Year Expenses 
  

						
	 Expense

	  	 Description

	  	Expense

	 FTE (Head Count)
	  	Sales and Marketing Staff	  	$	[***]
	 Conventions and Symposia
	  	ATS, CHEST, ACC, PHA	  	$	[***]
	 Promotional Materials
	  	Detail Aids, Journal Ads	  	$	[***]
	 CME
	  	New Therapies in PAH	  	$	[***]
	 National Speaker Training Meetings
	  	100 MDs	  	$	[***]
	 Community Advisory Panel Meetings
	  	250 MDs	  	$	[***]
	 	  	 	  	
	

	 Total
	  	 	  	$	[***]
	 	  	 	  	
	

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

									
	SCHERING	 	 	 	Quality Specification	 	 	 	Schedule 4
	 	 	 	 	No. LL64E260	 	 	 	to Exhale Agr.
	 	 	 	 	 	 	 	 	Part 1
	Iloprost, pure (variant)	 	 	 	 	 	 	 	Page: 1 of 3

  

 Date: 17 Aug 2001 
  
 Iloprost, pure (variant) 
 ZK No.
00036374 
  

							
	 Release:
	 	Gabriele Kadenbach	 	Responsible:	 	Dr. Moede
	 	 	sgd.	 	 	 	sgd.

  
 This Quality Specification takes
effect on 01 Nov 2001. 
  

			
	 Note:
	  	Caution: highly potent drug substance
		
	 	  	Avoid any contamination store at-18°C
		
	 	  	Observe the safety data sheet (SKD No. 1038 in the Schering safety database.
		
	 Art. No.
	  	01645167
		
	 This replaces:
	  	 Quality Specification of Testing Standard No 0040 g, issued 12 Sep 1991 (lloprost, pure, Art No. 00288878) Quality Specification No. 0040, issued
14 Aug 1991 (iloprost, reference standard)
 Quality Specification (shelf-life) of Testing Standard No. S 0061 d, issued 16 Aug 1991
 (lloprost, pure, Art No. 00288878)
 Quality Specification No.
LL64E250
 Quality Specification No. LL64EG10 (for Germany)

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

									
	SCHERING	 	 	 	Quality Specification	 	 	 	Schedule 4
	 	 	 	 	No. LL64E260	 	 	 	to Exhale Agr.
	 	 	 	 	 	 	 	 	Part 1
	Iloprost, pure (variant)	 	 	 	 	 	 	 	Page: 2 of 3

  

					
	 	  	 Release

	  	 Shelf-life:

			
	 Appearance:
	  	[***]	  	[***]
			
	 Identification of iloprost:
 (HPLC 4)
	  	[***]	  	[***]
			
	 Identification of iloprost:
 IR spectroscopy
	  	[***]	  	[***]
			
	 Specific optical rotation:
 (polarimetry)
	  	[***]	  	[***]
			
	 2-propanol:
 (GC)
	  	[***]	  	[***]
			
	 Methylene chloride:
 (GC)
	  	[***]	  	[***]
			
	 Ethyl acetate:
 (GC)
	  	[***]	  	[***]
			
	 Hexane:
 (GC)
	  	[***]	  	[***]
			
	 Methyl tert.-butyl ether:
 (GC)
	  	[***]	  	[***]
			
	 Acetic acid:
 (HPLC1)
	  	[***]	  	[***]
			
	 Water:
 (Karl Fischer method, coulometry)
	  	[***]	  	[***]

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

									
	SCHERING	 	 	 	Quality Specification	 	 	 	Schedule 4
	 	 	 	 	No. LL64E260	 	 	 	to Exhale Agr.
	 	 	 	 	 	 	 	 	Part 1
	Iloprost, pure (variant)	 	 	 	 	 	 	 	Page: 3 of 3

  

					
	 	  	 Release

	  	 Shelf-life:

			
	 Related substances/decomposition products of iloprost (except Z-isomers):
 (HPLC 2 and HPLC 3)
	  	[***]	  	[***]
			
	 Z-isomers (ZK 00036375) (HPLC 4)
	  	[***]	  	[***]
			
	 Isomer ratio of the E isomers:
 (HPLC 4)
	  	[***]	  	[***]
			
	 Iloprost:
 (HPLC 4)
	  	[***]	  	[***]

  
 Test procedure(s): 

 
 Conduct the tests as per Testing Standard No. LL64E150. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

									
	SCHERING	 	 	 	Quality Specification	 	 	 	Schedule 4
	 	 	 	 	No. MP81E240	 	 	 	to Exhale Agr.
	 	 	 	 	 	 	 	 	Part 2
	Ilomedin-10, solution for nebulizer	 	 	 	 	 	 	 	Page: 1 of 3

  

 Date: 08 Oct 2001 
  
 Ilomedin-10, solution for nebulizer 
  
 SH No.: L00401N 
  

							
	 Release:
	  	 Dr. Maja Hertsch
	  	 Responsible:
	  	 Dr. Moede

	 	  	 sgd.
	  	 	  	 sgd.

  
 This Quality Specification takes
effect on 01 Dec 2001. 
  
 This Quality Specification applies for: 
  
 Ilomedin-10, solution, 2.0 ml solution for inhalation, 3-ml glass ampul 
  

			
	Note:	  	 Caution: Highly potent medicinal product.

		
	 	  	 Observe the safety data sheet SKD No. 1038 for iloprost from the Schering safety database.

		
	 This replaces:
	  	 Quality Specification No. MP81E230.

  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION 

  

									
	SCHERING	 	 	 	Quality Specification	 	 	 	Schedule 4
	 	 	 	 	No. MP81E240	 	 	 	to Exhale Agr.
	 	 	 	 	 	 	 	 	Part 2
	Ilomedin-10, solution for nebulizer	 	 	 	 	 	 	 	Page: 2 of 3

  

					
	 	  	Release

	  	Shelf-Life

			
	 Appearance / visible particles:
 (visual test
1)
	  	[***]	  	[***]
			
	 Identification of iloprost:
 (TLC)
	  	[***]	  	[***]
			
	 Identification of iloprost:
 (HPLC 3)
	  	[***]	  	[***]
			
	 Identification of trometamol:
 (TLC)
	  	[***]	  	[***]
			
	 Identification of sodium:
 (flame
coloration)
	  	[***]	  	[***]
			
	 pH:
 (potentiometry)
	  	[***]	  	[***]
			
	 Filling volume:
 (volumetry)
	  	[***]	  	[***]
			
	 Color:
 (visual test 2)
	  	[***]	  	[***]
			
	 Related substances / decomposition products of iloprost
 (except Z-isomers):
 (HPLC 1 and HPLC 2)
	  	[***]	  	[***]
			
	 Iloprost:
 (HPLC 3)
	  	[***]	  	[***]
			
	 Sterility:
 (membrane filtration)
	  	[***]	  	[***]

  
 Test procedures: 
  
 Conduct the tests as per Testing Standard No. MP81E130. 
  

	*	CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSIONFORM OF SUPPLEMENTAL INDENTURE NO. 4

 Exhibit 4.6 
  
 FORM OF SUPPLEMENTAL INDENTURE NO. 4 
  
 FORM OF SUPPLEMENTAL INDENTURE NO. 4 (this “Supplemental
Indenture”), dated as of April 1, 2004, among Heritage Property Investment Trust, Inc., a Maryland corporation (the “Company”), Heritage Property Investment Limited Partnership, a Delaware limited partnership and a
subsidiary of the Company (“Heritage OP” and together with the Company, the “Guarantors”), Bradley Operating Limited Partnership, a Delaware limited partnership and a subsidiary of the Company (the
“Partnership”), and LaSalle Bank National Association, as trustee under the indenture referred to below (the “Trustee”). 
  
 W I T N E S S E T H 
  
 WHEREAS, the Partnership has previously executed and delivered to the Trustee an indenture (the “Indenture”), dated as of November 24,
1997 and three supplemental indentures, (a) Supplemental Indenture No. 1, dated as of November 24, 1997, providing for the issuance of an aggregate principal amount of $100,000,000 of 7% Notes due 2004, (b) Supplemental Indenture No. 2, dated as of
January 28, 1998, providing for the issuance of an aggregate principal amount of $100,000,000 of 7.2% Notes due 2008, and (c) Supplemental Indenture No. 3, dated as of March 10, 2000, providing for the issuance of an aggregate principal amount of
$75,000,000 of 8.875% Notes due 2006 (together, the “Notes”); 
  
 WHEREAS, simultaneously on the date hereof, the Company has executed and delivered to the Trustee an indenture (the “Company Indenture”) providing for the issuance by the Company of an aggregate
principal amount of up to $200,000,000 of 5.125% Notes due 2014 (the “Company Notes”); 
  
 WHEREAS, pursuant to the Company Indenture, Heritage OP and the Partnership are executing and delivering to the Trustee a supplemental indenture pursuant
to which each of Heritage OP and the Partnership will unconditionally guarantee all of the Company’s obligations under the Company Notes and the Company Indenture; 
  
 WHEREAS, in consideration for the Partnership’s execution of the guarantee referred to in the previous recital, the
Company and Heritage OP have agreed to execute this supplemental indenture pursuant to which each of the Company and Heritage OP shall unconditionally guarantee all of the Partnership’s obligations under the Notes and the Indenture (the
“Obligations”); 
  
 WHEREAS, pursuant to Section
901 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture. 
  
 NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, each of the
Guarantors and the Trustee mutually covenant and agree for the equal and ratable benefit of the holders of the Notes (“Holders”) as follows: 
  

1. CAPITALIZED TERMS. Capitalized terms used herein without definition shall have the meanings assigned to them in the
Indenture. 
  
 2. AGREEMENT TO
GUARANTEE. Each of the Guarantors hereby agrees as follows: 
  
 (a) Along with the other Guarantor named herein, to jointly and severally Guarantee to the Holders and their successors and assigns, that: 
  
 (i) the principal of, and interest on, the Notes will be promptly paid in full when due, whether at
maturity, by acceleration, redemption or otherwise, and interest on 

 the overdue principal of and interest on the Notes, if any, if lawful, and all other Obligations of the
Partnership to the Holders under the Indenture will be promptly paid in full or performed, all in accordance with the terms hereof and thereof; and 
  
 (ii) in case of any extension of time of payment or renewal of any Obligation, that same will be promptly paid in full when due or
performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration or otherwise. Failing payment when due of any amount so guaranteed or any performance so guaranteed for whatever reason, the Guarantors
shall be jointly and severally obligated to pay the same immediately. 
  
 (b) The obligations hereunder shall be unconditional, irrespective of the validity, regularity or enforceability of the Obligations, the absence of any action to enforce the same, any waiver or consent by any Holder with respect to any
provisions hereof or thereof, the recovery of any judgment against the Partnership, any action to enforce the same or any other circumstance which might otherwise constitute a legal or equitable discharge or defense of a Guarantor. 
  
 (c) The following is hereby waived: diligence, presentment, demand of
payment, filing of claims with a court in the event of insolvency or bankruptcy of the Partnership, any right to require a proceeding first against the Partnership, protest, notice and all demands whatsoever. 
  
 (d) This Guarantee shall not be discharged except by complete performance of
the Obligations, and each Guarantor accepts all Obligations. 
  
 (e) If any Holder is required by any court or otherwise to return to the Partnership, the Guarantors, or any custodian, trustee, liquidator or other similar official acting in relation to either the Partnership or the Guarantors, any amount
paid by such Holder, this Guarantee, to the extent theretofore discharged, shall be reinstated in full force and effect. 
  
 (f) A Guarantor shall not be entitled to any right of subrogation in relation to the Holders in respect of any Obligations guaranteed hereby until payment
in full of all Obligations guaranteed hereby. 
  
 (g) As between
the Guarantors, on the one hand, and the Holders and the Trustee, on the other hand, (x) the maturity of the Obligations guaranteed hereby may be accelerated as provided in Article Five of the Indenture for the purposes of this Guarantee,
notwithstanding any stay, injunction or other prohibition preventing such acceleration in respect of the Obligations guaranteed hereby, and (y) in the event of any declaration of acceleration of such Obligations as provided in Article Five of the
Indenture, such Obligations (whether or not due and payable) shall forthwith become due and payable by the Guarantors for the purpose of this Guarantee. 
  
 (h) A Guarantor shall have the right to seek contribution from any non-paying Guarantor so long as the exercise of such right does not impair the rights
of the Holders under this Guarantee. 
  
 (i) After giving effect
to any maximum amount and all other contingent and fixed liabilities that are relevant under any applicable Bankruptcy Law or fraudulent conveyance laws, and after giving effect to any collections from, rights to receive contribution from or
payments made by or on behalf of any other Guarantor in respect of the obligations of such other Guarantor under the Indenture, this Guarantee shall be limited to the maximum amount permissible such 
  

 -2- 

 that the obligations of a Guarantor under this Guarantee will not constitute a fraudulent transfer or
conveyance. 
  
 (j) Each payment to be made by a
Guarantor under this Guarantee in respect of the Obligations shall be payable in the currency or currencies in which such Obligations are denominated, and shall be made without set-off, counterclaim, reduction or diminution of any kind or nature.

  
 3. EXECUTION AND
DELIVERY. Each Guarantor agrees that the Guarantees shall remain in full force and effect notwithstanding any failure to endorse on each Note a notation of such Guarantee. 
  
 4. GUARANTOR MAY CONSOLIDATE, ETC. The ability of a Guarantor to
sell all or substantially all of its assets to, or consolidate with, or merge with or into another Person shall be governed by Article Eight of the Indenture. 
  

5. RELEASES. Subject to compliance with Section 4 hereof, in the event of any sale or other disposition of all or substantially all of
the assets of any Guarantor, by way of merger, consolidation or otherwise, or a sale or other disposition of all of the capital stock of any Guarantor, in each case to a Person that is not (either before or after giving effect to such transaction) a
subsidiary of the Company, then such Guarantor (in the event of a sale or other disposition, by way of merger, consolidation or otherwise, of all of the capital stock of such Guarantor) or the corporation acquiring the property (in the event of a
sale or other disposition of all or substantially all of the assets of such Guarantor) will be released and relieved of any obligations under its Guarantee. Upon delivery by the Partnership to the Trustee of an Officers’ Certificate and an
Opinion of Counsel to the effect that such sale or other disposition was made by the Partnership in accordance with the provisions of the Indenture and this supplemental indenture, the Trustee shall execute any documents reasonably required in order
to evidence the release of any Guarantor from its obligations under its Guarantee. 
  
 6. NO RECOURSE AGAINST OTHERS. No past, present or future director, officer, employee, incorporator, stockholder or agent of a Guarantor, as such, shall have
any liability for any obligations of the Partnership or any Guarantor under the Notes, the Indenture or this Supplemental Indenture or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of the
Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes. Such waiver may not be effective to waive liabilities under the federal securities laws and it is the
view of the Securities and Exchange Commission that such a waiver is against public policy. 
  
 7. NO OBLIGATION TO TAKE ACTION AGAINST THE PARTNERSHIP. Neither the Trustee nor any other Person
shall have any obligation to enforce or exhaust any rights or remedies or to take any other steps under any security for the Obligations or against the Partnership or any other Person or any Property of the Partnership or any other Person before the
Trustee is entitled to demand payment and performance by either or both Guarantors of their liabilities and obligations under this Guarantee. 
  
 8. DEFAULT AND ENFORCEMENT. If a Guarantor fails to pay in accordance with this Guarantee, the Trustee may
proceed in its name as trustee hereunder in the enforcement of the Guarantee of such Guarantor and such Guarantor’s obligations thereunder and hereunder by any remedy provided by law, whether by legal proceedings or otherwise, and to recover
from such Guarantor the obligations. 
  
 9. COSTS
AND EXPENSES. Each Guarantor shall pay on demand by the Trustee any and all costs, fees and expenses (including, without limitation, legal fees on a solicitor and client basis) incurred 
  

 -3- 

 by the Trustee, its agents, advisors and counsel or any of the Holders in enforcing any of their rights under this
Guarantee. 
  
 10. NEW YORK LAW TO GOVERN. THE INTERNAL LAW OF THE
STATE OF NEW YORK SHALL GOVERN AND BE USED TO CONSTRUE THIS SUPPLEMENTAL INDENTURE BUT WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED
THEREBY. 
  
 11. COUNTERPARTS. The parties may sign
any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. 
  
 12. EFFECT OF HEADINGS. The Section headings herein are for convenience only and shall not affect the
construction hereof. 
  
 13. THE
TRUSTEE. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are
made solely by the Guarantors and the Partnership. 
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 -4- 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and
attested, all as of the date first above written. 
  
 Dated: April
1, 2004 
  

			
	HERITAGE PROPERTY INVESTMENT LIMITED PARTNERSHIP
		
	By:	 	 
	 	 	

	 Name:
 Title:

	
	HERITAGE PROPERTY INVESTMENT TRUST, INC.
		
	By:	 	 
	 	 	

	 Name:
 Title:

	
	BRADLEY OPERATING LIMITED PARTNERSHIP
		
	By:	 	 
	 	 	

	 Name:
 Title:

	
	 LaSALLE NATIONAL BANK,
 As
Trustee

		
	By:	 	 
	 	 	

	 Authorized Signatory

  

 -5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]